

(Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use)

ver1.101 31-Aug-18

NHS England IN	FORMATION READER BOX	
Directorate		
Medical	Operations and Information	Specialised Commissioning
Nursing Finance	Trans. & Corp. Ops.	Commissioning Strategy

Document Purpose	Policy
	. Oney
Document Name	National Cancer Drug Fund List
Author	NHS England Cancer Drugs Fund Team
Publication Date	29 July 2016
Target Audience	Foundation Trust CEs, Medical Directors, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs, Patients; Patient Groups; Charities; Pharmaceutical Industry
Additional Circulation	
Description	
Cross Reference	National Cancer Drug Fund decision summaries
·	National Cancer Drug Fund decision summaries  National Cancer Drug Fund List (as updated July 2015)
Cross Reference Superseded Docs (if applicable)	
Cross Reference Superseded Docs (if applicable) Action Required Timing / Deadlines	National Cancer Drug Fund List (as updated July 2015)
Cross Reference Superseded Docs (if applicable) Action Required Timing / Deadlines (if applicable)	National Cancer Drug Fund List (as updated July 2015)  N/A
Cross Reference Superseded Docs	National Cancer Drug Fund List (as updated July 2015)  N/A  N/A
Cross Reference  Superseded Docs (if applicable)  Action Required  Timing / Deadlines (if applicable)  Contact Details for	National Cancer Drug Fund List (as updated July 2015)  N/A  N/A  NHS England Cancer Drugs Fund Team
Cross Reference  Superseded Docs (if applicable)  Action Required  Timing / Deadlines (if applicable)  Contact Details for	National Cancer Drug Fund List (as updated July 2015)  N/A  N/A  NHS England Cancer Drugs Fund Team Skipton House
Cross Reference  Superseded Docs (if applicable)  Action Required  Timing / Deadlines (if applicable)  Contact Details for	National Cancer Drug Fund List (as updated July 2015)  N/A  N/A  NHS England Cancer Drugs Fund Team Skipton House 80 London Road

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a

controlled document, this document should not be saved onto local or network drives but should

always be accessed from the intranet.

v1.101 31 August 2018

#### A. National CDF List

Notes:

This list should be read in conjunction with 'Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) A new deal for patients, taxpayers and industry' published by NHS England on 8 July 2016 at www.england.nhs.uk/ourwork/cancer/cdf

				Availab	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. The application is made by and the first cycle of systemic anti-cancer therapy with alectinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy									
			2. The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV non small cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement									
			3. The patient has received no previous ALK-targeted therapy									
			4. The patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non small cell lung cancer ie no previous systemic treatment except when this has been given as neoadjuvant or adjuvant therapy or concurrently with radiotherapy									
			5. Alectinib will be used only as single-agent therapy									
		Alectinib for untreated anaplastic	6. The patient has an ECOG performance status of 0 or 1 or 2									
ALE1_v1.0	Alectinib	lymphoma kinase-positive advanced non- small-cell lung cancer where the following	7. The patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting alectinib	F	rom 28-Jun-1	18	No	n/a	Yes	Yes	No	06-Nov-18
			8. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner									
			9. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle									
			10. Alectinib will be otherwise used as set out in its Summary of Product Characteristics									
			11. In cases of intolerance to alectinib, either ceritinib or crizotinib is to be used only if the patient has not had progressive disease whilst on alectinib. Neither ceritinib nor crizotinib are to be used following disease progression on alectinib as there is no current clear evidence to support treatment with ceritinib or crizotinib after disease progression on alectinib. Alectinib cannot be used in any line other than 1st line as the manufacturer chose not to make a submission to NICE for its licensed indication for use after crizotinib									

				Availab	ole to new p	oatients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
ARS1_v1.1	Arsenic trioxide	Arsenic trioxide for treating newly diagnosed low to intermediate risk acute promyelocytic leukaemia in ADULTS where all the following criteria are met:	<ol> <li>An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient is an ADULT and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene</li> <li>The patient is newly diagnosed with acute promyelocytic leukaemia</li> <li>The patient has low to intermediate risk acute promyelocytic leukaemia (white cell count ≤10 x 10°/L) and has not received any chemotherapy for this.</li> <li>Patients with high risk acute promyelocytic leukaemia are not funded for treatment with arsenic trioxide</li> <li>The patient will be treated with induction treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA)</li> <li>Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 60, arsenic trioxide will be discontinued</li> <li>As consolidation therapy, a maximum of 4 cycles of arsenic trioxide will be prescribed, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</li> <li>The dosing and schedule of administration of arsenic trioxide will be either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 trial as reported in Lancet Oncology 2015; 16:1295-1305.</li> <li>If the AML17 dosing and schedule is used, hospital Trust policy regarding unlicensed treatments should be followed</li> <li>The treating team is aware of the risk of and the treatment for</li> <li>APL differentiation syndrome</li> <li>QT interval prolongation and the need for monitoring of electrolytes</li> <li>Liver toxicity</li> <li>The use of arsenic trioxide is excluded from the</li></ol>	Fı	rom 04-May-	18	No	n/a	Yes	Yes	No	11-Sep-18

v1.101 31 August 2018

				Availab	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
ARS2_v1.1	Arsenic trioxide	criteria are met:	1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. This patient is an ADULT and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RARalpha) gene 3. The patient has acute promyelocytic leukaemia which is EITHER refractory to or relapsed after previous treatment which included a retinoid and chemotherapy OR has relapsed after a complete remission which lasted at least 2 years following previous arsenic trioxide and all-trans-retinoic acid treatment 4. The patient will be treated with induction and consolidation treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA) As combination therapy with ATRA is unlicensed in this relapsed/refractory setting, hospital Trust policy regarding unlicensed treatments should be followed 5. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 50 if the dosing and schedule is used as in the Summary of Product Characteristics or by day 60 if the UK NCRI AML 17 protocol is used (Lancet Oncology 2015; 16: 1295-1305), arsenic trioxide will be discontinued 6. As consolidation therapy, either the dosing and schedule in the Summary of Product Characteristics used for a maximum of 5 weeks or the dosing and schedule of administration of arsenic trioxide will be either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 protocol.  If the AML17 dosing and schedule is used, hospital Trust policy regarding unlicensed treatments should be followed 8. The treating team is aware of the risk of and the treatment for  * APL differentiation syndrome * QT interval prolongation and the need for monit	Fı	rom 04-May-	18	No	n/a	Yes	Yes	No	11-Sep-18

				Availab	ble to new ¡	patients		Transition	Eligible for	_	CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
ARS3_v1.1	Arsenic trioxide	Arsenic trioxide for treating newly diagnosed low to intermediate risk acute promyelocytic leukaemia in CHILDREN where the following criteria are met:	<ol> <li>1. An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>2. The patient is a CHILD and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RARalpha) gene</li> <li>3. The patient is newly diagnosed with acute promyelocytic leukaemia (white cell count ≤10 x 10<sup>9</sup>/L) and has not received any chemotherapy for this.</li> <li>Patients with high risk acute promyelocytic leukaemia are not funded for treatment with arsenic trioxide</li> <li>5. The patient will be treated with induction treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA)</li> <li>6. Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 60, arsenic trioxide will be discontinued</li> <li>7. As consolidation therapy, a maximum of 4 cycles of arsenic trioxide will be prescribed, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</li> <li>8. The patient is a pre-pubescent or post-pubescent child and will be treated with the dosing and schedule of administration of arsenic trioxide either in accordance with that described in the Summary of Product Characteristics (SPC) or that used in the UK NCRI AML17 trial as reported in Lancet Oncology 2015; 16: 1295-1305.</li> <li>9. The use of arsenic trioxide has been discussed at a multi-disciplinary team (MDT) meeting which must include two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area</li> <li>10. The hosp</li></ol>		rom 04-May-	18	No	n/a	Yes	Yes	No	11-Sep-18

v1.101 31 August 2018

				Availal	ble to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable
ARS4_v1.1	Arsenic trioxide	Arsenic trioxide for treating relapsed/refractory acute promyelocytic leukaemia in CHILDREN where the following criteria have been met:	<ol> <li>An application is made by and the start of systemic anti-cancer therapy with arsenic trioxide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient is a CHILD and has a confirmed diagnosis of acute promyelocytic leukaemia characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RARalpha) gene</li> <li>The patient has acute promyelocytic leukaemia which is EITHER refractory to or relapsed after previous treatment which included a retinoid and chemotherapy OR has relapsed after a complete remission which lasted at least 2 years following previous arsenic trioxide and all-trans-retinoic acid treatment</li> <li>The patient will be treated with induction and consolidation treatment of arsenic trioxide in combination with all-trans-retinoic acid (ATRA)</li> <li>As combination therapy with ATRA is unlicensed in this relapsed/refractory setting, hospital Trust policy regarding unlicensed treatments should be followed</li> <li>Induction treatment with arsenic trioxide will be continued until complete remission is achieved but if complete remission is not achieved by day 50 if the dosing and schedule is used as in the Summary of Product Characteristics or by day 60 if the UK NCRI AML 17 protocol is used (Lancet Oncology 2015; 16: 1295-1305), arsenic trioxide will be discontinued</li> <li>As consolidation therapy, either the dosing and schedule in the Summary of Product Characteristics is used for a maximum of 5 weeks or the dosing and scheduling of the UK NCRI AML17 protocol (Lancet Oncology 2015; 16: 1295-1305) is used for a maximum of 4 cycles of arsenic trioxide, each cycle being 4 weeks on treatment followed by 4 weeks off therapy</li> <li>The patient is a pre-pubescent or post-pubescent child and will be treated with the dosing and schedule of administration of arsenic trioxide either in accordance</li></ol>	F	rom 04-May-	-18	No	n/a	Yes	Yes	No	11-Sep-18

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. An application has been made by and the first cycle of systemic anti-cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.									
			2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.									
			3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract									
			<ul> <li>4. The patient has disease that is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)</li> <li>5. The patient has not received previous chemotherapy for inoperable locally advanced or metastatic urothelial cancer</li> </ul>									
			6. The patient has EITHER not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy OR, if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy, has relapsed more than 12 months since completing the platinum-based chemotherapy  * Patients meeting this criterion are eligible to be considered as treatment naïve for locally advanced/ metastatic disease but must satisfy all other criteria									
			7. The patient has an ECOG performance status (PS) of 0, 1 or 2.  Note: treatment of patients of performance status 2 should only proceed with caution as there is limited safety data on PS 2 patients with urothelial cancer treated with atezolizumab.									
ATE1_v1.1	Atezolizumab	The first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy where all the following criteria are met:	8. The patient is ineligible for platinum-based chemotherapy, due to <b>one or more of the following</b> :  * impaired renal function (EDTA-assessed glomerular filtration rate >30 and <60mls/min)  * hearing loss of 25dB as assessed by formal audiometry  * NCI CTCAE grade 2 or worse peripheral neuropathy  * ECOG PS 2		rom 01-Nov-	17	No	n/a	nca	nca	Yes	nca
			9. The patient's urothelial tumour has undergone PD-L1 testing									
			10. A PD-L1 expression of ≥5% has been recorded and the measurement used for PD-L1 testing is defined as the presence of discernible PD-L1 staining of any intensity in tumour infiltrating immune cells covering ≥5% of tumour area occupied by tumour cells, associated intra-tumoural and contiguous peri-tumoural desmoplastic stroma									
			11. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody	j-								
			12. The patient has no symptomatically active brain metastases or leptomeningeal metastases									
			13. Atezolizumab is being given as monotherapy and will commence at a fixed dose of 1200mg every 3 weeks									
			14. A formal medical review as to whether treatment with atezolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment									
			15. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner									
			16. Treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle									
			17. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).									

				Availak	ble to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			<ol> <li>An application is made by and the first cycle of systemic anti-cancer therapy with avelumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to</li> </ol>									
			anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis  2. The nations has a confirmed histological or susplagical diagnosis of Markel coll									
			3. The patient has a confirmed histological or cytological diagnosis of Merkel cell carcinoma									
			4. The patient has metastatic disease									
			5. The patient is treatment naïve to any systemic anti-cancer therapy for Merkel cell carcinoma and in particular has not received any prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] antibody									
AVE1_v1.0	Avelumab	The treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma where all the following	6. The patient has an ECOG performance status of either 0 or 1. Note: a patient with a performance status of 2 or more is not eligible for avelumab		om 01-Mar-2	018	No	n/a	Yes	Agreed	Yes	nca
		criteria are met:	7. If the patient has brain metastases, then these have been treated and are stable									
			8. Avelumab is to be used as monotherapy only									
			9. Avelumab is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment. I also confirm that patients with radiological disease progression not associated with significant clinical deterioration (defined as no new or worsening symptoms <b>and</b> no change in performance status for greater than 2 weeks <b>and</b> no need for salvage therapy: all 3 conditions must apply) can continue treatment									
			10. A formal medical review as to whether treatment with avelumab should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment									
			<ul> <li>11. Treatment breaks of up to 12 weeks beyond the expected cycle length of avelumab are allowed but solely to allow immune toxicities to settle</li> <li>12. Avelumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</li> </ul>									
			Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy     Low grade non-Hodgkin's lymphoma									
		The treatment of released law are de-	3. Relapsed disease									
BEN6_v2.1	Bendamustine	The treatment of relapsed low grade lymphoma where all the following criteria	4. Unable to receive CHOP-R  5. Unable to receive FCR		From 29-Jul-1	16	Yes	Agreed	nca	nca	nca	nca
		are met:	6. Unable to receive high dose-therapy					<b>0</b>				
			7. No prior bendamustine  8. To be used within the treating Trust's governance framework, as Bendamustine is									
			8. To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication  Note: Can be used in combination with Rituximab, which is commissioned by NHS									
			England for this indication.									

				Availal	ble to new p	oatients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
BEN5_v2.1	Bendamustine	The treatment of relapsed multiple myeloma where all the following criteria are met:	<ol> <li>Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Multiple myeloma</li> <li>Relapsed disease where all other treatments contraindicated or inappropriate</li> <li>To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication</li> </ol>		From 29-Jul-1	6	Yes	Agreed	nca	nca	nca	nca
BEV2_v1.4	Bevacizumab	The first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy where all the following criteria are met:	8. The patient has no contraindications to the use of bevacizumab  9. Bevacizumab dose to be 15mg/kg every 3 weeks  10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process  Note: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy  Note: Bevacizumab should be discontinued for reasons of toxicity or disease		From 29-Jul-1	6	Yes	Agreed	nca	nca	nca	nca
BEV8_v1.3	Bevacizumab	The third line treatment of low grade gliomas of childhood where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant paediatric specialist specifically trained and accredited in 2. Progressive low grade glioma 3. No previous treatment with either irinotecan or bevacizumab 4. Irinotecan and bevacizumab to be the 3rd or further line of therapy 5. A maximum of 12 months duration of treatment to be used with a re-application required at 6 months 6. Consent with the parent/guardian to specifically document the unknown long term toxicity of this combination, particularly on growth and ovarian function 7. To be used within the treating Trust's governance framework, as Bevacizumab and Irinotecan are not licensed in this indication in children 8. In the period immediately prior to the application for irinotecan and bevacizumab, the appropriate specialist MDT has considered the use of proton beam radiotherapy.  NOTE: Bevacizumab is ONLY approved for use in combination with combination chemotherapy and is not approved for use as a single agent maintenance therapy NOTE: Additional data on long term toxicity must be collected by the paediatric oncology community		From 29-Jul-1	6	Yes	Agreed	nca	nca	nca	nca

				Availak	ole to new p	patients		Transition	Eligible for	Interim Funding	CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
BEV3_v2.1	Bevacizumab	The first line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Chemotherapy naïve advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (not licensed at this dosage)  3. 1st line indication  4. Patients must satisfy one of the following criteria:  i) FIGO stage III debulked but residual disease more than 1cm OR  iii) Stage IV disease OR  iii) Stage III at presentation and requiring neo-adjuvant chemotherapy due to low likelihood of optimal primary surgical cytoreduction  5. Given with Carboplatin and Paclitaxel combination chemotherapy  6. Bevacizumab to start with:  1st or 2nd cycle of chemotherapy following primary debulking surgery, OR  1st or 2nd cycle of chemotherapy following interval debulking surgery performed after 3-4 cycles of neo-adjuvant chemotherapy, OR  1st or 2nd cycles of chemotherapy for those patients with stage IV disease or inoperable disease, OR  1st cycle of neo-adjuvant chemotherapy  7. Bevacizumab dose to be 7.5mg/kg every 3 weeks and NOT 15mg/kg every 3 weeks  8. Maximum of 18 cycles of Bevacizumab  9. As this dosage of Bevacizumab is not licensed in ovarian cancer it must be used within the treating Trust's governance framework  Note: This policy is NOT for patients with stage I-III disease who have had optimal debulking  Note: These criteria also apply to patients entered into the ICON 8b trial. Clinicians should be aware that for patients randomised to the non-bevacizumab arm of ICON 8b, the use of bevacizumab in subsequent lines of treatment is not approved under current CDF criteria.		From 29-Jul-1	.6	Yes	Agreed	nca	nca	nca	nca
BOR1_v2.1	Bortezomib	The treatment of bortezomib naive relapsed multiple myeloma where all the following criteria are met:	Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy     Relapsed myeloma     No previous Bortezomib		From 29-Jul-1	.6	Yes	Agreed	nca	nca	nca	nca

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
BRE5_v1.3	Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multiagent chemotherapy is not a treatment option in ADULT patients where the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient is an adult*  *note there is a separate blueteq form to be used for brentuximab in this indication in children  3. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.  4. The patient has relapsed Hodgkin lymphoma after at least 2 prior systemic therapies when either autologous stem cell transplant or further multi-agent chemotherapy is not a treatment option.  5. The patient has had no previous stem cell transplant  6. The patient has never received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-1  7. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response  8. I confirm that no more than 16 cycles of brentuximab may be administered per patient  9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process  10. No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion*  *note there is a separate blueteq form for such re-use of brentuximab  11. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).		From 29-Jul-	16	Yes	Agreed	Yes	Yes	nca	11-Sep-18

				Availal	ble to new p	<u>patients</u>		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
BRE6_v1.2	Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multiagent chemotherapy is not a treatment option in CHILD patients where the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002  http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378  *note there is a separate Bluteq form to be used for brentuximab in this indication in adults.  3. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.  4. The patient has relapsed Hodgkin lymphoma after at least 2 prior systemic therapies when either autologous stem cell transplant or further multi-agent chemotherapy is not a treatment option.  5. The patient has had no previous stem cell transplant  6. The patient has never received brentuximab  7. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response  8. I confirm that no more than 16 cycles of brentuximab may be administered per patient  9. The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.  10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process  11. No re-use of brentuximab will be used outside this indication unless		From 29-Jul-1	.6	Yes	Agreed	Yes	Agreed	nca	11-Sep-18

				Availak	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
CABO3_v1.0	Cabozantinib	The treatment of treatment-naïve intermediate or poor risk advanced renal cell carcinoma where the following criteria are met:	1. Application is made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. This patient has a confirmed histological diagnosis of renal cell carcinoma (RCC) with a clear cell component  3. The patient has either metastatic disease or inoperable locally advanced disease  4. The patient is treatment naïve to systemic therapy and in particular has previously received neither any vascular endothelial growth factor (VEGF)-targeted systemic therapy nor mTOR pathway inhibitor-targeted treatment unless prior treatment with pazopanib or sunitinib or tivozanib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of progressive disease  5. The patient has intermediate risk OR poor risk advanced renal cell carcinoma as defined by the International Metastatic Renal Cell Carcinoma Database Consortium. Good risk patients are not eligible for cabozantinib therapy.  Intermediate risk is defined as having 1 or 2 risk factors and poor risk as having ≥3 factors, these factors being:  - Time from diagnosis of RCC to need for systemic therapy of <1 year  - Haemoglobin < lower limit of normal  - Corrected calcium > upper limit of normal  - Corrected calcium > upper limit of normal  - Karnofsky performance status <80%  - Neutrophils > upper limit of normal  6. The patient has an ECOG performance status of either 0 or 1 or 2  7. If the patient has brain metastases, then these have been treated and are stable  8. Cabozantinib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment  9. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment  10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle	F	rom 24-Aug-	18	No	n/a	Yes	Agreed	No	tbc
CLO2_v2.0	Clofarabine	The treatment of relapsed/refractory acute myeloblastic leukaemia where all the following criteria are met:	1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Acute myeloblastic leukaemia (not licensed for this indication)  3. Relapsed/ refractory disease with intent to use treatment to bridge to bone marrow transplant  4. To be used within the treating Trust's governance framework, as Clofarabine is not licensed for this indication		From 29-Jul-1	6	Yes	Agreed	nca	nca	nca	nca

				Availak	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
CLO1_v2.0	Clofarabine	The treatment of relapsed/refractory acute lymphoblastic leukaemia where all the following criteria are met:	<ol> <li>Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Acute lymphoblastic leukaemia</li> <li>Relapsed/ refractory disease with intent to use treatment to bridge to bone marrow transplant</li> </ol>		From 29-Jul-1	.6	Yes	Agreed	nca	nca	nca	nca
CRI3_v1.0	Crizotinib	1st or subsequent line systemic therapy for ROS1-positive inoperable locally advanced/metastatic non squamous nonsmall cell lung cancer	1. I confirm that this application is made by and the first cycle of systemic anticancer therapy with crizotinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. I confirm that the patient has a histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer that is either stage IIIB or stage IV  3. I confirm that this non squamous NSCLC carries a confirmed ROS1 gene rearrangement as demonstrated by an accurate and validated assay  4. I confirm that the patient has received no previous ROS1-targeted therapy  5. I confirm that EITHER the patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non-small cell lung cancer OR has been previously treated with cytotoxic chemotherapy for locally advanced or metastatic disease  Note: NHS England has a strong preference for ROS1-positive patients to be treated with crizotinib as 1st line therapy for locally advanced/metastatic NSCLC though recognises that some patients have had to be treated with chemotherapy for urgent clinical reasons before the ROS1 result was known  6. I confirm that crizotinib will be used only as single-agent therapy  7. I confirm that the patient has an ECOG performance status of 0 or 1 or 2  8. I confirm that the patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting crizotinib  9. I confirm that the patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner  10. I confirm that treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle  11. I confirm that crizotinib will be otherwise used as set out in its Summary of Product Characteristics (SPC)	F	rom 31-May-	-18	No	nca	Yes	Agreed	Yes	nca

				Availal	ble to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable
DAR1_v1.0	Daratumumab	The treating relapsed and refractory multiple myeloma where all the following criteria are met:	1. This application is made by and the first cycle of systemic anti-cancer therapy with daratumumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. The patient has a diagnosis of multiple myeloma.  3. The patient has received 3 and no more than 3 prior lines of treatment and that the numbering of these lines of treatment is in accordance with the International Myeloma Workshop Consensus recommendations for the uniform reporting of clinical trials (http://doi.org/10.1182/blood-2010-10-299487. A line of therapy is defined as one or more cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner (eg induction chemotherapy and stem cell transplantation is considered to be 1 line of therapy, a new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease.  Note: The use of daratumumab will be audited to confirm it is being used in accordance with these treatment criteria (particularly in respect of lines of therapy) and non-compliant use will be monitored and followed-up.  4. The patient has responded to at least 1 of these 3 lines of treatment.  5. In relation to the immediately previous line of systemic therapy, the patient has: documented relapse of disease after, initial response or refractory disease.  6. The patient has been previously treated with a proteasome inhibitor.  7. The patient has been previously treated with an immunomodulatory agent.  8. I have informed the CDF as to whether the patient has been treated with a previous stem cell transplant (SCT) or not:  9. The patient has had no previous therapy with daratumumab or an anti-CD38 antibody  11. Daratumumab is only to be used as a sin		From 17-Jan-1	18	No	nca	Yes	Agreed	Yes	nca

				Availab	ole to new	patients	Transition Drug (Old	Transition Funding agreed by	Eligible for Interim Funding	agreed by manufacturer	CDF Managed Access Scheme	Expected Entry into Baseline Commissioning
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	CDF) Indication (Yes or No)	manufacturer (Agreed,	(Yes, No, Not currently applicable (NCA))	(Agreed, Rejected, Pending, Not currently applicable (NCA))	(Yes, No, Not currently applicable (NCA))	(Date if known or Not currently applicable (NCA))
DIN1_v1.0	Dinutuximab beta	Dinutuximab beta as part of 1st line therapy for high risk neuroblastoma in patients aged 12 months and above and who have both responded to induction chemotherapy and been treated with myeloablative therapy and stem cell transplantation where the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy with dinutuximab beta will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for hypersensitivity reactions, capillary leak syndrome, neuropathic pain, peripheral neuropathy and ocular toxicity  3. The patient is currently aged 12 months or older and has histologically documented neuroblastoma according to the International Neuroblastoma Staging System (INSS)  4. The patient has high risk disease defined as either INSS stage 2, 3, 4 and 4s with MYCN amplification or INSS stage 4 without MYCN amplification and aged >12 months at diagnosis  5. The patient achieved at least a partial response to induction chemotherapy  6. The patient was treated with myeloablative therapy and stem cell transplantation  7. The patient remains free of disease progression following induction chemotherapy and stem cell transplantation  8. The patient has not received prior treatment with an anti-GD2 antibody antibody unless transitioning from the company's current access scheme for high risk patients and provided that all other treatment criteria listed here are fulfilled  9. Dinutuximab beta is not being given in combination with interleukin-2  10. A formal medical review as to whether treatment with dinutuximab beta should continue or not and at what dose will be scheduled to occur at least by the end of the first cycle of treatment  11. The patient will be treated until disease progression or excessive toxicity or completion of 5 cycles of therapy or patient/parent/guardian (as appropriate) choice to discontinue treatment, whichever is the sooner  12. Treatment breaks of up to 6 weeks beyond the expected cycle length are allowed  13. Dinutuximab beta will otherwise be used as set out in its Summary of Product Characteristics (SPC)		From 12-Jul-	18	No	nca	Yes	Agreed	No	20-Nov-18

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy with dinutuximab beta will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for hypersensitivity reactions, capillary leak syndrome, neuropathic pain, peripheral neuropathy and ocular toxicity</li> </ol>									
DIN2_v1.0	Dinutuximab beta	in patients aged 12 months and above and who have then both responded to intensive induction chemotherapy used to	5. The patient achieved at least a partial response to induction chemotherapy		From 12-Jul-1	18	No	nca	Yes	Agreed	No	20-Nov-18
		treat high risk 1st line patients and been treated with myeloablative therapy and stem cell transplantation where the following criteria are met:	6. The patient was treated with myeloablative therapy and stem cell transplantation 7. The patient remains free of disease progression following induction chemotherapy and stem cell transplantation 8. The patient has not received prior treatment with an anti-GD2 antibody 9. Dinutuximab beta is not being given in combination with interleukin-2 10. A formal medical review as to whether treatment with dinutuximab beta should continue or not and at what dose will be scheduled to occur at least by the end of the first cycle of treatment 11. The patient will be treated until disease progression or excessive toxicity or completion of 5 cycles of therapy or patient/parent/guardian (as appropriate) choice to discontinue treatment, whichever is the sooner 12. Treatment breaks of up to 6 weeks beyond the expected cycle length are allowed									
			13. Dinutuximab beta will otherwise be used as set out in its Summary of Product Characteristics (SPC)									

				Availa	ble to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable
			The application has been made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  The potient has a configured eliminate the logical discussive of Woldenstreet's	-								
			2. The patient has a confirmed clinicopathological diagnosis of Waldenstrom's Macroglobulinaemia (WM) and meets the consensus panel criteria from the Second International Workshop on WM (Owen RG 2003 - https://www.ncbi.nlm.nih.gov/pubmed/12720135)									
			3. The patient has symptomatic disease meeting at least one of the recommendations for requiring active treatment as set out in the Second International Workshop on WM (Kyle et al 2003 - https://www.ncbi.nlm.nih.gov/pubmed/12720119).  4. Presence of documented progression of disease:  * After response to previous line of treatment OR  * No response to previous line of systemic therapy	-								
IBR4_v1.1	Ibrutinib	The treatment of Waldenstrom's Macroglobulinaemia where all the	5. The patient has received at least 1 prior line of treatment  6. The patient has received the following previous treatments (please select one or more as relevant): Chlorambucil single agent; Rituximab single agent; Bendamustine single agent; Chlorambucil plus rituximab; Bendamustine plus rituximab; FCR; Cladribine plus rituximab; DRC; Bortezomib combination; Other		From 28-Sep-	-17	No	nca	nca	nca	Yes	nca
		following criteria are met:	<ul><li>7. The patient has never received any B cell receptor therapies (ibrutinib, idelalisib, acalabrutinib)</li><li>8. Ibrutinib is to be used as a single agent</li></ul>									
			9. Ibrutinib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment	-								
			10. The patient's performance status is 0, 1 or 2									
			11. The patient's neutrophil count is ≥1 x 10°/L									
			12. The patient's platelet count ≥50 x 10 <sup>9</sup> /L									
			13. The patient is not on concurrent therapy with warfarin or CYP3A4/5 inhibitors									
			14. no treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)									
			15. ibrutinib will be otherwise used as set out in its Summary of Product Characteristics									

				Availa	able to new p	atients			Eligible for	Interim Funding		
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected Pending)	Interim Funding (Yes, No, Not	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
INO1_v1.0	Inotuzumab ozogamicin	The treatment of relapsed/refractory Philadelphia positive and Philadelphia negative B cell precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy with inotuzumab ozogamicin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is fully aware of the risk factors for inotuzumab ozogamicin inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction syndrome and that this risk rises as the number of cycles administered increases  3. The patient has relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Please tick appropriate box as to which type of ALL the patient has:  * Philadelphia chromosome negative ALL or  * Philadelphia chromosome positive ALL in which case treatment with at least one second or third generation TKI must have also failed  4. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage  5. The patient is an adult*  * note there is a separate Blueteq form to be used for inotuzumab ozogamicin in this  6. Inotuzumab ozogamicin will only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed/refractory ALL and who have regular ALL multi-disciplinary team meetings and close links with bone marrow transplant centres  7. The patient has an ECOG performance status of 0 - 2  8. The following treatment duration policy will apply to the use of inotuzumab ozogamicin: for those patients proceeding to a stem cell transplant (SCT), the recommended duration of treatment is 2 cycles. A 3rd cycle may be considered for those patients who do not achieve a complete remission (CR) or a CR with incomplete haematological recovery (CRi) and minimal residual disease negativity after 2 cycles. For patients not proceeding to a SCT, a maximum of 6 cycles of treatment may be administered. Patients who do not achieve a CR or CRi within 3 cycles should	Fro	om 09-Aug-2	018	No	nca	Yes	Yes	No	tbc

				Availa	ble to new p	atients				Interim Funding		
Blueteq Form ref:	Drug		Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Funding (Yes, No, Not	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
INO2_v1.0	Inotuzumab ozogamicin	in CHILD patients where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy with inotuzumab ozogamicin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is fully aware of the risk factors for inotuzumab ozogamicin inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction inducing hepatotoxicity including veno-occlusive liver disease/sinusoidal obstruction syndrome and that this risk rises as the number of cycles administered increases  3. The patient has relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).  Please tick appropriate box as to which type of ALL the patient has:  * Philadelphia chromosome negative ALL or  * Philadelphia chromosome positive ALL in which case treatment with at least one second or third generation TKI must have also failed  4. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage chemotherapy or blinatumomab  5. The patient is a child* and:  - is post pubescent or  - is pre-pubescent and will receive inotuzumab ozogamicin at the dosage described in the results of the inotuzumab ozogamicin trial in children and reported in Pediatric Blood Cancer 2014; 61: 369-372 doi: 10.1002/pbc.24721  *note there is a separate Blueteq form to be used for inotuzumab ozogamicin in this indication in adults.  6. Inotuzumab ozogamicin will only be requested by and administered in principal treatment centres  7. The use of the inotuzumab ozogamicin has been discussed at a multi-disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups ap		om 09-Aug-20	018	No	nca	Yes	Yes	No	tbc

				Availa	able to new p	atients				Interim Funding		
Blueteq Form ref:	Drug		Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Transition Funding agreed by manufacturer (Agreed, Rejected, Pending)	Funding (Yes, No, Not	agreed by	Access Scheme (Yes, No, Not currently applicable (NCA))	Expected Entry into Baseline Commissioning (Date if known or Not currently applicable (NCA))
IXA1_v1.1	Ixazomib with lenalidomide and dexamethasone	The treament of relapsed or refractory multiple myeloma where all the following criteria are met:	1. The application was made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. The patient has a confirmed diagnosis of multiple myeloma.  3. Lonfirm that the patient has received 2 or 3 prior lines of treatment and that the numbering of these lines of treatment is in accordance with the International Myeloma Workshop Consensus recommendations for the uniform reporting of clinical trials (Inttp://doi.org/10.1182/blood-2010-10-299487). A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner (eg induction chemotherapy and stem cell transplantation is considered to be 1 line of therapy). A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse or toxicity. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease. Please indicate the number of prior lines of treatment:  Note: The use of ixazomib will be audited to confirm it is being used in accordance with these treatment criteria (particularly in respect of lines of therapy) and non-compliant use will be monitored and followed-up.  Note: Patients previously treated with 1 or >3 lines of treatment are not eligible for ixazomib.  4. The patient is neither refractory to previous proteasome inhibitor-based nor lenalidomide-based treatment at any line of therapy (in this context, refractory disease is defined as disease progression on treatment or disease progression within 60 days of the last dose of a proteasome inhibitor or lenalidomide).  Note: As lenalidomide is only commissioned by NHS England after 2 prior therapies, the only eligible	F	From 19-Dec-1	17	No	nca	Yes	Yes	Yes	nca

				Availal	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. This application is made by and the first cycle of systemic anti-cancer therapy with lenvatinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy									
			2. This patient has a confirmed histological diagnosis of differentiated thyroid	-								
			carcinoma (papillary or follicular or Hurtle cell type)  3. The patient has either metastatic disease or inoperable locally advanced disease	-								
			4. The disease is refractory to radioactive iodine									
			5. The disease is progressive and is either symptomatic or imminently likely to become symptomatic	_								
LNV2_v1.0	Lenvatinib	The treatment of differentiated thyroid cancer after radioactive iodine where all the following criteria are met:	6. The patient is treatment naïve to both lenvatinib and sorafenib unless <b>either</b> : a) previously enrolled in the company's lenvatinib compassionate access scheme and all other NHS England treatment criteria are fulfilled ie if treated with previous sorafenib, lenvatinib will only be accepted for NHS funding if the patient was intolerant of sorafenib according to the conditions set out in b) below <b>or</b> b) the patient has had to discontinue sorafenib within 3 months of starting sorafenib because of toxicity (ie there is sorafenib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on sorafenib		From 15-Feb-	18	No	nca	Yes	Agreed	No	06-Nov-18
			Note: Sequential use of lenvatinib and then sorafenib is only funded if the patient has to discontinue lenvatinib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on lenvatinib. The use of lenvatinib after disease progression on or after sorafenib is not funded and vice versa.									
			7. The patient has an ECOG performance status of 0 or 1 or 2									
			8. Lenvatinib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment  9. A formal medical review as to whether treatment with lenvatinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment  10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)  11. Lenvatinib is to be otherwise used as set out in its Summary of Product	-								

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No,	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. This application is made by a consultant oncologist who is specifically trained and accredited in the use of systemic anti-cancer therapy and who is a core member of the relevant Neuroendocrine Carcinoma Multi-Disciplinary Team (MDT)									
			2. The Neuroendocrine Carcinoma MDT has confirmed the arrangements by which only persons authorised to handle radiopharmaceuticals (such as lutetium oxodotreotide) do so in authorised clinical settings and after evaluation of the patient by an appropriately trained and accredited physician									
			3. The patient has a histologically documented, well differentiated neuroendocrine carcinoma of the gastrointestinal tract or pancreas									
			Note: patients with primary bronchial neuroendocrine carcinomas are not eligible for treatment with lutetium oxodotreotide									
			4. The patient's disease is either unresectable or metastatic									
			5. The patient's disease is somatostatin receptor positive on imaging (on PET									
			scanning but otherwise on scintigraphy if PET scanning not possible) and this									
		or metastatic, progressive, well	imaging confirms overexpression of somatostatin receptors in the tumour tissue with the tumour uptake at least as high as normal liver uptake (tumour uptake grade score $\geq$ 2)									
LUT1_v1.0	Lutetium oxodotreotide	differentiated and somatostatin receptor positive gastroenteropancreatic neuroendocrine carcinoma where all the following criteria are met:	6. There has been recent demonstration in this patient of disease progression on CT or MR imaging over the course of a maximum period of 3 years	F	From 20-Jul-:	18	No	n/a	Yes	Agreed	No	27/11/2018
			7. The patient has an ECOG performance status (PS) score of 0 or 1 or 2									
			8. The patient has not received prior treatment with lutetium oxodotreotide									
			Note: re-treatment with a further program of lutetium oxodotreotide treatments is not commissioned									
			9. Lutetium oxodotreotide is being given as monotherapy (bar somatostatin analogues in between treatments) and will involve a maximum of 4 infusions of 7400 MBq as long as there is no evidence of disease progression									
			10. A formal face to face medical review as to whether treatment with lutetium oxodotreotide should continue or not will be scheduled to occur before each of the 4 planned treatment administrations									
			11. The presciribing clinician notes that the use of lutetium oxodotreotide is exempt from the NHS England cancer drug Treatment Breaks policy									
			12. Lutetium oxodotreotide will otherwise be used as set out in its Summary of Product Characteristics (SPC)									

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. An application is made by and the first cycle of systemic anti-cancer therapy with midostaurin will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy									
			2. The patient is an adult and has a confirmed diagnosis of acute myeloid leukaemia									
			3. The patient has a FLT3 mutation as determined by a validated test									
			4. The patient is newly diagnosed with FLT3 positive acute myeloid leukaemia and									
			has not received any chemotherapy for this  5. The patient is fit for intensive induction chemotherapy									
		Midostaurin for treating FLT3 mutation	6. The patient will be treated with midostaurin in combination with standard									
MID1_v1.1	Midostaurin	positive acute myeloid leukaemia in adults	daunorubicin and cytarabine induction chemotherapy and in combination with high	Fi	rom 04-May-	-18	No	n/a	Yes	Agreed	No	11-Sep-18
_		where the following criteria are met:	dose cytarabine consolidation chemotherapy		,			,		J		'
			Midostaurin is excluded from the NHS England Treatment Breaks Policy.  7. As maintenance monotherapy, midostaurin is to be only used in patients in									
			complete remission of their AML									
			8. In the maintenance monotherapy phase, a maximum of 12 28-day cycles of midostaurin will be used									
			9. If the patient proceeds to a stem cell transplant, midostaurin will be permanently discontinued prior to the stem cell transplant conditioning regimen									
			10. Midostaurin is to be otherwise used as set out in its Summary of Product Characteristics									

				Availab	ole to new p	oatients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
NIR1_v1.0	Niraparib	and high grade serous ovarian, fallopian	<ol> <li>This application is made by and the first cycle of systemic anti-cancer therapy with niraparib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The prescribing clinicians is fully aware of the likely toxicities of niraparib, the associated monitoring required and the reasons why 48% of patients in the ENGOT-OV16/NOVA trial had dose interruptions in the 1st cycle and 47% commenced their 2nd cycle at a reduced niraparib dosage</li> <li>The patient has a confirmed histological diagnosis of predominantly high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma</li> <li>The patient has had a germline BRCA test</li> <li>The patient HAS a documented germline BRCA mutation</li> <li>The patient relapsed following 1st line chemotherapy (ie the penultimate line of treatment) and had platinum-sensitive disease at this relapse, platinum sensitivity defined by a complete or partial remission which lasted for more than 6 months following completion of 1st line platinum-based chemotherapy (whether given preand/or post-operatively or if the patient did not have surgery)</li> <li>The patient is in a complete or partial response following completion of 2nd line platinum-based chemotherapy (ie the most recent chemotherapy) and that the serum CA125 is either normal or has demonstrated a &gt;90% decrease from before the initiation of 2nd line chemotherapy and is stable</li> <li>The patient is less than 12 weeks since completing 2nd line chemotherapy</li> <li>The patient has not previously received any PARP inhibitor</li> <li>The patient has not previously received any PARP inhibitor</li> <li>The patient has not previously received any PARP inhibitor</li> <li>The patient has not previously received any exist of either 0 or 1. A patient with a performance status of 2 or more is not eligible for niraparib</li> <li>Niraparib is to be continued until disease progression</li></ol>	F	rom 01-Jun-1	18	No	nca	Yes	Agreed	Yes	nca

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
NIR2_v1.0	Niraparib	and high grade serous ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based SECOND OR LATER line chemotherapy and who DO NOT HAVE a germline BRCA mutation where the following criteria are met:	1. This application is made by and the first cycle of systemic anti-cancer therapy with niraparib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. The prescribing clinician is fully aware of the likely toxicities of niraparib, the associated monitoring required and the reasons why 48% of patients in the ENGOT-OV16/NOVA trial had dose interruptions in the 1st cycle and 47% commenced their 2nd cycle at a reduced niraparib dosage 3. The patient has a confirmed histological diagnosis of predominantly high grade serous epithelial ovarian, fallopian tube or primary peritoneal carcinoma 4. The patient has had a germline BRCA test 5. The patient DOES NOT HAVE a documented germline BRCA mutation 6. The patient relapsed following the penultimate line of chemotherapy (ie the line of treatment preceding the most recent line of chemotherapy) and had platinumsensitive disease at this relapse, platinum sensitivity defined by a complete or partial remission which lasted for more than 6 months following completion of this penultimate line of platinum-based chemotherapy 7. The patient is in a complete or partial response following completion of the most recent line platinum-based chemotherapy which must be at least second line treatment and that the serum CA125 is either normal or has demonstrated a >90% decrease from before the initiation of this most recent line of chemotherapy and is stable Note: Please state on the form what line of treatment was the most recent line of treatment 8. The patient has not previously received any PARP inhibitor 10. The patient has an ECOG performance status of either 0 or 1. A patient with a performance status of 2 or more is not eligible for niraparib 11. Niraparib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment 12. A formal medical review as to whether maintenance treatment with niraparib should continue or not and at what dose will be scheduled to occur at l	F	rom 01-Jun-	18	No	nca	Yes	Agreed	Yes	nca

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
NIV4_v1.0	Nivolumab	The treatment of previously treated locally advanced or metastatic non-squamous non-small cell lung cancer	1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient has a confirmed diagnosis of stage IIIB or IV non-squamous non-small cell lung cancer  3. The patient has progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive  5. The patient has an ECOG performance status of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2 <sup>nd</sup> line chemotherapy.  5. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the nivolumab EAMS programme for this indication and the patient meets all other criteria listed here  6. The patient has had PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score.  7. The patient's tumour expresses PD-L1 (that is, with a tumour proportion score (TPS) ≥ 1%) by an approved and validated test.  8. The patient's tumour proportion score* (TPS) is:  * Note: the patient's TPS must be provided, otherwise the application will not be authorised.  9. Nivolumab will be administered as monotherapy.  10. The patient has no symptomatically active brain metastases or leptomeningeal metastases.  11. Nivolumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.  *Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.	Fı	rom 20-Sept	-17	No	nca	nca	nca	Yes	nca
			12. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 11.									

				Availal	ble to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
NIV5_v1.0	Nivolumab	The treatment of previously treated locally advanced or metastatic <b>squamous</b> non-small cell lung cancer	1. An application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. As the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.  3. The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV squamous non-small cell lung cancer.  4. The patient has progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive.  5. The patient has an ECOG performance status of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2 <sup>nd</sup> line chemotherapy.  6. The patient has not received prior treatment with an anti-PD-1,	F	rom 20-Sept-	-17	No	nca	nca	nca	Yes	nca

				Availab	ole to new	patients		Transition	Eligible for	Interim Funding	CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
NIV6_v1.0	Nivolumab	The treatment of recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy where all the following crtieria are met:	7. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.  8. Every effort has been made for the patient to have PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score (TPS). Please document the TPS results below:  - TPS (if negative enter zero): OR  - Please enter 'yes', if the TPS cannot be quantified OR  - Please enter 'yes', if PD-L1 testing was not possible as the pathologist has documented that these was insufficient tissue  9. Nivolumab will be administered as monotherapy.  10. The patient has no symptomatically active brain metastases or leptomeningeal metastases.  11. Nivolumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.  *Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until further disease progression is confirmed.  12. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 11.	F	rom 13-Oct-	17	No	nca	nca	nca	Yes	nca
NEL1_v2.0	Nelarabine	ICELLIVMUNDUISSTIC NON-HOOGKIN'S	Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy      Application made by and first cycle of systemic anti-cancer therapy to be systemic and accredited in the use of systemic anti-cancer therapy      Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy to be systemic anti-cancer therapy therapy to be systemic anti-cancer therapy to be systemic anti-cancer therapy to be systemic anti-cancer therapy therapy therapy therapy to be systemic anti-cancer therapy therapy therapy therapy therapy therapy therapy therapy th	F	From 29-Jul-1	16	Yes	Agreed	nca	nca	nca	nca

				Availat	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)		Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			<ol> <li>An application has been made by and the first cycle of systemic anti -cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>The patient has a confirmed histological diagnosis of follicular lymphoma.</li> </ol>									
			3. The patient has been previously treated for follicular lymphoma with rituximab-containing chemotherapy (i.e. with induction rituximab-containing chemotherapy followed if appropriate by maintenance rituximab therapy).									
			<ul> <li>4. The patient has not previously received treatment with bendamustine unless completed more than 2 years previously.</li> <li>5. A maximum of 6 cycles of the combination of obinutuzumab plus bendamustine should be used and followed in responding patients or in those with stable disease with maintenance single agent obinutuzumab once every 2 months for a maximum of 2 years or until disease progression (whichever occurs first).</li> </ul>									
OBIBEN1_v1.0	Obinutuzumab with bendamustine	The treatment of follicular lymphoma refractory to rituximab where the following criteria apply:	6a. The patient has either failed to respond to or progressed during rituximab- containing combination induction chemotherapy, OR	1	from 27-Jul-1	7	No	Agreed	nca	nca	Yes	nca
			6b. The patient has progressed during or within 6 months of completing maintenance single agent rituximab - please indicate how many months since completion of previous induction rituximab-containing combination chemotherapy progression occurred.									
			7. The patient has an ECOG performance status (PS) of 0 - 2. 8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).									
			*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process.									
			9. The licensed doses and frequencies of obinutuzumab and bendamustine will be used.									

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
OLA1_v1.0	Olaratumab	In combination with doxorubicin for the treatment of advanced soft tissue sarcoma in ADULT patients where the following criteria apply:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has histologically proven soft tissue sarcoma.</li> <li>The patient has locally advanced or metastatic disease.</li> <li>The patient is an adult*         <ul> <li>*note there is a separate Bluteq form to be used for olaratumab in this indication in children.</li> <li>Treatment intent is palliative ie disease not amenable to potentially curative treatment with surgery and/or radiotherapy.</li> <li>The patient has had no previous treatment with doxorubicin.</li> </ul> </li> <li>Olaratumab will be administered in combination with doxorubicin 75mg/m².</li> <li>A maximum of 6 cycles of doxorubicin will be given.</li> <li>Olaratumab when given concurrently with chemotherapy will only be used in combination with doxorubicin (ie not with a doxorubicin-containing combination or non-doxorubicin containing regimen)</li> <li>The patient has an ECOG performance status (PS) 0 or 1.</li> <li>The patient has either not received previous adjuvant or neoadjuvant chemotherapy or has but this was not with any doxorubicin-containing regimen.</li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</li> <li>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</li> <li>Olaratumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).</li> </ol>		rom 09-Jun-	17	No	n/a	Yes	Agreed	Yes	nca

				Availat	ble to new ¡	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and									
			accredited in the use of systemic anti-cancer therapy									
			2. The patient has histologically proven soft tissue sarcoma.									
			3. The patient has locally advanced or metastatic disease.									
			4. The patient is a post pubescent child*.									
			*note there is a separate Blueteq form to be used for olaratumab in this indication in adults.									
			5. Olaratumab will only be requested by and administered in principal treatment									
			centres.									
			6. The use of the olaratumab has been discussed at a multi disciplinary team (MDT)									
			meeting which must include at least two consultants in the subspecialty with active									
			and credible expertise in the relevant field of whom at least one must be a									
			consultant paediatrician. The MDT should include a paediatric pharmacist and other									
			professional groups appropriate to the disease area.									
			7. Treatment intent is palliative ie disease not amenable to potentially curative									
			treatment with surgery and/or radiotherapy.									
		In combination with doxorubicin for the treatment of advanced soft tissue	8. The patient has had no previous treatment with doxorubicin.	_	- 00.1			,			,	
OLA2_v1.1	Olaratumab	sarcoma in PAEDIATRIC patients where	9. Olaratumab will be administered in combination with doxorubicin 75mg/m².		From 09-Jun-1	L/	No	n/a	Yes	Agreed	n/a	nca
		the following criteria apply:	10. A maximum of 6 cycles of doxorubicin will be given.									
			11. Olaratumab will be administered until disease progression/unacceptable toxicity									
			12. Olaratumab when given concurrently with chemotherapy is only to be used in									
			combination with doxorubicin (ie not with a doxorubicin-containing combination or									
			non-doxorubicin containing regimen)  13. The nations has an ECOC performance status (BS) 0 or 1									
			13. The patient has an ECOG performance status (PS) 0 or 1.	-								
			14. The patient has either not received previous adjuvant or neoadjuvant chemotherapy or has but this was not with any doxorubicin-containing regimen.									
			15. No planned treatment breaks of more than 6 weeks beyond the expected cycle									
			length are allowed (to allow any toxicity of current therapy to settle or intercurrent									
			comorbidities to improve).*									
			*Requests for continuation of treatment after unplanned treatment breaks over this									
			duration should be made via the treatment break approval process									
			16. Trust policy regarding unlicensed treatments should be followed as olaratumab									
			is not licensed in this indication in children  17. Olaratumab will otherwise be used as set out in its Summary of Product									
			Characteristics (SPC).									
			Characteristics (SEC).						1			

v1.101 31 August 2018

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
OSI1_v1.0	Osimertinib	The treatment of locally advanced or metastatic epidermal growth factor receptor and T790M mutation-positive non-small-cell lung cancer (NSCLC) where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Histologically or cytologically documented NSCLC that carries an EGFR and a T790M mutation</li> <li>Locally advanced or metastatic NSCLC</li> <li>Radiological documentation of disease progression following 1st line EGFR TKI treatment with only one TKI and without any further systemic anti-cancer treatment.</li> <li>Treatment with no more than one prior line of treatment for advanced NSCLC</li> <li>No prior chemotherapy unless any prior neoadjuvant or adjuvant chemotherapy had been completed at least 6 months prior to starting 1st line EGFR treatment</li> <li>ECOG PS 0 or 1</li> <li>At time of starting osimertinib, the patient must be fit enough to have potentially started platinum-based doublet chemotherapy</li> </ol>	F	rom 04-Oct-í	16	No	n/a	nca	nca	Yes	nca
PLD1_v2.2		The treatment of sarcomas where all the following criteria are met:	<ol> <li>An application has been made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>a) Sarcoma in patients with cardiac impairment requiring an anthracycline, 1st line indication, OR</li> <li>b) Sarcoma in patients with cardiac impairment requiring an anthracycline, 2nd line indication</li> <li>To be used within the treating Trust's governance framework, as Pegylated Liposomal Doxorubicin is not licensed in these indications</li> </ol>		From 29-Jul-1	.6	Yes	Agreed	nca	nca	nca	nca

				Availab	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
PEMB2_v1.1	Pembrolizumab	The treatment of untreated PD-L1 positive metastatic non-small-cell lung cancer where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</li> <li>The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer (squamous or non-squamous)</li> <li>The patient's tumour expresses PD-L1 (that is, with a tumour proportion score [TPS] ±50%) by an approved and validated test</li> <li>The patient either does not have an adenocarcinoma/non-squamous histology OR does have an adenocarcinoma/non-squamous histology but does not have an EGFR or ALK-positive tumour</li> <li>The patient has not received previous systemic therapy for advanced /metastatic disease. Completion of treatment with CT and/or RT as part of neoadj/adj therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease</li> <li>The patient has an ECOG performance status (PS) of 0 or 1 and is potentially fit for platinum-based chemotherapy</li> <li>The patient has not received prior treatment with an anti-PD-1, anti-PD-12, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless received as part of the pembrolizumab EAMS programme for this indication and meeting all other criteria listed.</li> <li>Pembrolizumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.</li> <li>*Atypical responses (i.e., an initial transient increase in tumour size or small new lesions within the first few months followed by tumour shrinkage) have been observed. It is recommended to continue treatment for cli</li></ol>	Fı	rom 31-May-	17	No	n/a	Yes	Agreed	Yes	16-Oct-18

				Availab	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
PEMB3_v1.0	Pembrolizumab	The treatment of locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy	1. An application has been made by and the first cycle of systemic anti-cancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis  3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract  4. The patient's disease is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)  5. There has been disease progression during or following previous platinum-based combination chemotherapy for inoperable locally advanced or metastatic urothelial cancer  6. The patient has either: not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy, or if previously treated with platinum-based chemotherapy or with chemo-radiotherapy, has relapsed <= 12 months since completing the platinum-based chemotherapy*  * Patients meeting this criterion are eligible to be considered as previously treated for locally advanced/ metastatic disease but must satisfy all other criteria  7. The patient has an ECOG performance status (PS) score of 0 or 1 or 2 Note: treatment of patients with performance status 2 should only proceed with caution as there is limited safety data on PS 2 patients with urothelial carcinoma treated with pembrolizumab  8. The patient has not received prior treatment with an anti-PD-1, anti-PD-1, anti-PDL2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the pembrolizumab compassionate use programme for this indication and the patient meets all other criteria listed here  9. Pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusi	F	rom 16-Mar-1	18	No	n/a	Yes	Agreed	Yes	nca
			14. The patient has no symptomatically active brain metastases or leptomeningeal metastases     15. Pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC)									

				Availab	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
PEMB4_v1.0	Pembrolizumab	The treatment of first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy	1. An application has been made by and the first cycle of systemic anti-cancer therapy with peembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.  3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract  4. The patient has disease that is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N MI disease)  5. The patient has disease that is either locally advanced (ie T4b any N or any T N2-3 disease) or metastatic (any T any N MI disease)  5. The patient has not received previous chemotherapy for inoperable locally advanced or metastatic urothelial cancer  6. The patient has EITHER not received previous adjuvant chemotherapy, necadjuvant chemotherapy or chemor-radiotherapy for localised urothelial cancer OR, if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as necadjuvant chemotherapy or or with chemo-radiotherapy for localised urothelial cancer, has relapsed more than 12 months since completing the platinum-based chemotherapy or as necadjuvant chemotherapy or with chemo-radiotherapy for localised urothelial cancer, has relapsed more than 12 months since completing the platinum-based chemotherapy.  * Patients meeting this criterion are eligible to be considered as treatment naïve for locally advanced/ metastatic disease but must satisfy all other criteria  7. The patient has an ECOG performance status (2°) of 0,1 or 2  Note: treatment of patients with performance status 2° with pembrolizumab should only proceed with caution as there is limited safety data on PS 2 patients with urothelial carcinoma treated with pembrolizumab  7. The patient i	F	rom 27-Apr-1	18	No	n/a	Yes	Agreed	Yes	nca

				Availak	ole to new p	patients		Transition	Eligible for Interim		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Funding (Yes. No.	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
PEMB5_v1.0	Pembrolizumab	The treatment of relapsed or refractory classical Hodgkin lymphoma in ADULTS who are stem cell transplant-ineligible and have failed brentuximab vedotin	1. I confirm that an application has been made by and the first cycle of systemic anticancer therapy with pembrolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anticancer therapy.  2. I confirm that as the prescribing clinician I am fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.  3. I confirm that the patient is an ADULT and has histologically documented classical Hodgkin lymphoma  Note: there is a separate Blueteq form to be used for pembrolizumab in this indication in children  4. I confirm that the patient has failed at least 2 lines of chemotherapy and also treatment with brentuximab vedotin  5. I confirm that the patient has not received stem cell transplantation of any kind  6. I confirm that the patient has not received stem cell transplantation  7. I confirm that the patient is currently ineligible for stem cell transplantation  7. I confirm that the patient is sufficient benefit of treatment with pembrolizumab OR is not a candidate for stem cell transplantation however good the response to pembrolizumab may be.  8. I confirm that the patient has an ECOG performance status (PS) of 0 or 1  9. I confirm that the patient has not received prior treatment with an anti-PD-1, anti-PD-1, anti-PD-12, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody  10. I confirm that pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusion  11. I confirm that a pembrolizumab is being given as monotherapy and will commence at a fixed dose of 200mg per infusion  12. I confirm that a pembrolizumab is being given as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment  12. I confirm that the patient will be treated until stem cel		From 25-Jul-1	.8	No	n/a	Yes	Agreed	Yes	nca

				Availab	ole to new p	patients		Transition	Eligible for	Interim Funding	CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)		Transition Drug (Old CDF) Indication (Yes or No)		Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
PEMB6_v1.0	Pembrolizumab	The treatment of relapsed or refractory classical Hodgkin lymphoma in CHILDREN who are stem cell transplant-ineligible and have failed brentuximab vedotin	(CTLA-4) antibody  10. I confirm that pembrolizumab is to be given as monotherapy  11. I confirm that the patient is a pre-pubescent or post-pubescent child and will be treated with the 2mg/Kg dosing (maximum dose 200mg) and 3-weekly schedule of pembrolizumab as used in the clinical trial NCT03407144  12. I confirm that the use of pembrolizumab has been discussed at a multidisciplinary team (MDT) meeting which must include 2 consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area  13. The hospital Trust policy regarding unlicensed treatments has been followed as pembrolizumab is not licensed in this indication in children  14. I confirm that a formal medical review as to whether treatment with pembrolizumab should continue or not will be scheduled to occur at least by the end of the third cycle of treatment  15. I confirm that the patient will be treated until stem cell transplantation occurs or loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner  16. I confirm that the patient will receive a maximum treatment duration with pembrolizumab of 2 years		From 25-Jul-1	18	No	n/a	Yes	Agreed	Yes	nca
			17. I confirm that treatment breaks of up to 12 weeks beyond the expected cycle length are allowed but solely to allow immune toxicities to settle  18. I confirm that pembrolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).									

				Availab	le to new	patients		Transition	Eligible for	Interim Funding	CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	1. This application is made by and the first cycle of systemic anti-cancer therapy with sorafenib will be prescribed by a consultant specialist specifically.	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
SOR2_v3.0	Sorafenib	The treatment of differentiated thyroid cancer after radioactive iodine where the following criteria are met:	therapy with sorafenib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. This patient has a confirmed histological diagnosis of differentiated thyroid carcinoma (papillary or follicular or Hurtle cell type)  3. The patient has either metastatic disease or inoperable locally advanced disease  4. The disease is refractory to radioactive iodine  5. The disease is progressive and is either symptomatic or imminently likely to become symptomatic  6. The patient is treatment naïve to both lenvatinib and sorafenib unless the patient has had to discontinue lenvatinib within 3 months of starting lenvatinib because of toxicity (ie there is lenvatinib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on lenvatinib	F	rom 29-Jul-:	16	Yes	Agreed	Yes	Agreed	nca	06-Nov-18

				Availab	ole to new	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use  1. This application is made by and the first cycle of systemic anti-cancer therapy with	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed, Rejected, Pending)	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	(Yes, No,	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
			1. This application is made by and the first cycle of systemic anti-cancer therapy with vandetanib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy									
			2. This patient has a confirmed histological diagnosis of medullary thyroid carcinoma									
			3. The patient has either metastatic disease or inoperable locally advanced disease									
			4. The disease is progressive and is either symptomatic or imminently likely to become symptomatic									
		The first line treatment of medullary	5. The patient is treatment naïve to both vandetanib and cabozantinib unless the patient has had to discontinue cabozantinib within 3 months of starting cabozantinib because of toxicity (ie there is cabozantinib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on cabozantinib									
VAN1_v2.3	Vandetanib	thyroid cancer where all the following criteria are met:	Note: The sequential use of vandetanib and then cabozantinib is only funded if the patient has to discontinue vandetanib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on vandetanib. The use of cabozantinib after disease progression on or after vandetanib is not funded and vice versa		From 29-Jul-1	16	Yes	Agreed	nca	nca	nca	nca
			6. The patient has an ECOG performance status of 0 or 1.									
			7. Vandetanib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment									
			8. A formal medical review as to whether treatment with vandetanib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment									
			9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)									
			10. Vandetanib is to be otherwise used as set out in its Summary of Product Characteristics									

				Availak	ole to new p	patients		Transition	Eligible for		CDF Managed	Expected Entry
Blueteq Form ref:	Drug	Indication	Criteria for use	Yes	Yes (but notice of removal served)	No	Transition Drug (Old CDF) Indication (Yes or No)	Funding agreed by manufacturer (Agreed,	Interim Funding (Yes, No, Not currently applicable (NCA))	agreed by manufacturer (Agreed, Rejected, Pending, Not currently applicable (NCA))	Access Scheme (Yes, No, Not currently applicable (NCA))	into Baseline Commissioning (Date if known or Not currently applicable (NCA))
VEN1_v1.0	Venetoclax	Treatment of chronic lymphatic leukaemia in the <b>ABSENCE</b> of 17p deletion (and absence of TP53 mutation if tested)	1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Confirmed diagnosis of chronic lymphatic leukaemia or small lymphocytic lymphoma that requires treatment  3. Patient has been tested for 17p deletion and the result is negative. If TP53 mutation has been tested, then it must be negative too.  4. Patient must also either have progressive disease on or after chemoimmunotherapy  5. Patient must also either have progressive disease on or after treatment with a B cell receptor pathway inhibitor: a Bruton's tyrosine kinase inhibitor (BTKi eg ibrutinib) or a PI3K inhibitor (PI3Ki eg idelalisib) or have a contraindication to receiving both a BTKi and a PI3Ki. Please indicate which: ibrutinib. idelalisib or contraindication  6. Patient has an ECOG performance status of 0-2  7. Patients has been prospectively assessed for the risk of the development of tumour lysis syndrome following the start of venetoclax  8. Patient has been assessed specifically for potential drug interactions with venetoclax  9. Venetoclax is to be used as a single agent  10. Venetoclax is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment  11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)  12. Venetoclax to be otherwise used as set out in its Summary of Product Characteristics		From 05-Oct-1	17	No	nca	nca	nca	Yes	nca
VEN2_v1.0	Venetoclax	The treatment of chronic lymphatic leukaemia in the <b>PRESENCE</b> of 17p deletion or TP53 mutation where all of the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Confirmed diagnosis of chronic lymphatic leukaemia or small lymphocytic lymphoma that requires treatment  3. Patient is positive for testing for 17p deletion or TP53 mutation  4. Patient must either have relapsed on or after a B cell receptor pathway inhibitor (a Bruton's tyrosine kinase inhibitor [BTKi eg ibrutinib] or a PI3K inhibitor [eg idelalisib]) or there must be a contraindication to the patient receiving both a BTKi and a PI3Ki. Please indicate which: ibrutinib, idelalisib or contraindication  5. Patient has a performance status of 0-2  e 6. Patients has been prospectively assessed for the risk of the development of tumour lysis syndrome following the start of venetoclax  7. Patient has been assessed specifically for potential drug interactions with venetoclax  8. Venetoclax is to be used as a single agent  9. Venetoclax is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment  10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)  11. Venetoclax to be otherwise used as set out in its Summary of Product Characteristics		From 05-Oct-1	17	No	nca	nca	nca	Yes	nca

## B. NICE approved and baseline funded drugs/indications from 1st April 2016

Notes:

If no Blueteq approval criteria are set this is because this was not considered necessary at the time of approval. However Blueteq registration will be required for all cancer drugs moving from the CDF to baseline as a result of positive final NICE guidance from 7th December 2016.

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
		2. I confirm that the patient has documented castration-resistant metastatic prostate cancer	-			
	Abiraterone for treating metastatic	3. I confirm that the patient has no or mild symptoms after androgen deprivation therapy has failed.	-			
Abiraterone	hormone-relapsed prostate cancer before chemotherapy is indicated	<ul> <li>4. I confirm that chemotherapy is not yet indicated.</li> <li>5. I confirm that ONE of the following applies to this patient:</li> <li>OPTION 1 - The patient has not previously received treatment with enzalutamide.</li> <li>OPTION 2 - The patient has previously received enzalutamide but it was stopped within 3 months of starting due to dose limiting toxicity and there is clear absence of disease progression.</li> </ul>	Yes	TA387	27-Apr-16	26-Jul-16
		6. I confirm abiraterone is to be given in combination with prednisolone.				
		<ol> <li>I confirm the licensed dose and frequency of abiraterone will be used.</li> <li>An application has been made by and the first cycle of systemic anti -cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.</li> </ol>				
		3. The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer and is either non-squamous or squamous in type.				
		4. The patient has either progressed after previously receiving at least 2 cycles of platinum-containing chemotherapy for stage IIIB or IV non-small cell lung cancer and also a targeted treatment if the tumour is EGFR positive or ALK positive or progressed within 6 months of completing platinum-based chemotherapy given as adjuvant or neoadjuvant therapy or concurrent with radiotherapy				
Atezolizumab	Atezolizumab for treating previously platinum-treated locally advanced/ metastatic <b>non squamos</b> or <b>squamos</b> non-small cell lung cancer which has been prospectively determined before this application to be PD-L1 positive or PD-L1	5. PD-L1 testing with an approved and validated test to determine the Tumour Proportion Score (TPS) has been attempted prior to this application. Either:  - The TPS score will be documented  - The TPS score cannot be documented as the TPS result was unquantifiable  - PD-L1 testing was not possible as the pathologist has documented that there is insufficient tissue for PD-L1 analysis	No	TA520	16-May-18	14-Aug-18
Atezolizumab	negative or PD-L1 unquantifiable at PD-L1 assay or one in which PD-L1 status cannot be determined on account of insufficient	6. The patient has a performance status (PS) of 0 or 1 and would otherwise be potentially fit for docetaxel-based 2nd line chemotherapy	·	14320	10-1VIay-18	14-Aug-10
	lung cancer tissue being available for PD-	7. The patient has no symptomatically active brain metastases or leptomeningeal metastases.				
	L1 assay where all the following criteria are met:	8. Atezolizumab will be administered as monotherapy  9. The patient has not received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody				
		10. Atezolizumab will be stopped at 2 years of treatment or on loss of clinical benefit or unacceptable toxicity, whichever occurs first.				
		11. A formal medical review as to whether treatment with atezolizumab should continue or not will be scheduled to occur at least by the end of the first 9 weeks of treatment				
		12. Treatment breaks of up to 12 weeks beyond the expected cycle length of atezolizumab are allowed solely to allow immune toxicities to settle				
		13. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC) with the exception of criterion 10.				

v1.101 31 August 2018

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Atezolizumab	Atezolizumab for locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy where all the following criteria are met:	1. The application is made by and the first cycle of systemic anti-cancer therapy with atezolizumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis  3. The patient has histologically or cytologically documented transitional cell carcinoma of the urothelial tract  4. The patient's disease is either locally advanced (i.e. T4b any N or any T N2-3 disease) or metastatic (any T any N M1 disease)  5. The patient has either not received previous adjuvant chemotherapy, neoadjuvant chemotherapy or chemo-radiotherapy, or if previously treated with platinum-based chemotherapy whether as adjuvant chemotherapy or as neoadjuvant chemotherapy or with chemo-radiotherapy, has relapsed ≤ 12 months since completing the platinum-based chemotherapy*  * Patients meeting this criterion are eligible to be considered as previously treated for locally advanced/ metastatic disease (and can answer "Yes" to criteria 6 below) but must satisfy all other criteria  6. There has been disease progression during or following previous platinum-based combination chemotherapy for inoperable locally advanced or metastatic urothelial cancer  7. The patient has an ECOG performance status (PS) score of 0 or 1  8. The patient has not received prior treatment with an anti-PD-1, anti-PD-12, anti-PD12, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless it was received as part of the atezolizumab compassionate use programme for this indication and the patient meets all other criteria listed here  9. Atezolizumab is being given as monotherapy and will commence at a fixed dose of 1200mg per infusion  10. A formal medical review as to whether treatment with atezolizumab should continue or	No	TA525	13-Jun-18	started 13-Jul-18
		15. Atezolizumab will otherwise be used as set out in its Summary of Product Characteristics (SPC)	1			

v1.101 31 August 2018

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Avelumab	The treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma where all the following criteria are met:	1. An application is made by and the first cycle of systemic anti-cancer therapy with avelumab will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for the immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis  3. The patient has a confirmed histological or cytological diagnosis of Merkel cell carcinoma  4. The patient has metastatic disease  5. I confirm that the patient has previously been treated with cytotoxic chemotherapy for metastatic Merkel cell carcinoma and has not received any prior treatment with any anti-PD-1, anti-PD-12, anti-PD-12, anti-CD137 or anti-cytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] antibody  6. The patient has an ECOG performance status of either 0 or 1. Note: a patient with a performance status of 2 or more is not eligible for avelumab  7. If the patient has brain metastases, then these have been treated and are stable  8. Avelumab is to be used as monotherapy only  9. Avelumab is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment. I also confirm that patients with radiological disease progression not associated with significant clinical deterioration (defined as no new or worsening symptoms and no change in performance status for greater than 2 weeks and no need for salvage therapy: all 3 conditions must apply) can continue treatment  10. A formal medical review as to whether treatment with avelumab should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment  11. Treatment breaks of up to 12 weeks beyond the expected cycle length of avelumab are allowed but solely to allow immune toxicities to settle  12. Avelumab will otherwise be used as set out in its Summary of Product Characteristics (SPC)	No	TA517	11-Apr-18	10-Jul-18
Bendamustine	The first line treatment of low grade lymphoma where all the following criteria are met:	<ol> <li>Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Low grade non-Hodgkin's lymphoma</li> <li>Option for 1st-line chemotherapy only</li> <li>To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication</li> <li>Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.</li> </ol>	Yes	n/a - NHS England clinical policy	-	08-Jul-18
Bendamustine	The first line treatment of mantle cell non- Hodgkin's lymphoma where all the following criteria are met:	<ol> <li>Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Mantle cell non-Hodgkin's lymphoma</li> <li>1st-line treatment in patients unsuitable for standard treatment</li> <li>To be used within the treating Trust's governance framework, as Bendamustine is not licensed in this indication</li> <li>Note: Can be used in combination with Rituximab, which is commissioned by NHS England for this indication.</li> </ol>	Yes	n/a - NHS England clinical policy	-	08-Jul-18

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).				
		3. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy or inotuzumab ozagamicin				
		4. The patient is an adult* *note there is a separate Blueteq form to be used for blinatumomab in this indication in children.	n Yes TA450 27-Apr-17			
Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute	5. Blinatumomab should only be requested by and administered in either bone marrow transplant centres or in major haematological centres that regularly treat patients with relapsed ALL and who have close and regular ALL multi-disciplinary team meetings and links with bone marrow transplant centres.		TA450 27 A52 47	26-Sep-17	
	lymphoblastic leukaemia in ADULT patients	6. The patient has an ECOG performance status of 0 - 2.		<b>10 00p</b> 17		
	patients	7. A maximum of 5 cycles of treatment with blinatumomab will be administered.				
		8. Blinatumomab will be used as monotherapy				
		9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		10. Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).				
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has relapsed or refractory Philadelphia negative acute lymphoblastic leukaemia (ALL).				
		3. The patient has been previously treated with intensive combination chemotherapy as initial treatment with or without subsequent salvage therapy or inotuzumab ozagamicin				
		<ul> <li>4. The patient is a child* and</li> <li>is either post pubescent or</li> <li>is pre pubescent and will receive blinatumomab at the dosage described in the phase 2 part of the blinatumomab trial protocol</li> <li>NCT01471782 and reported in J Clin Oncol 2016; 34: 4381-4389</li> <li>*note there is a separate Blueteq form to be used for blinatumomab in this indication in adults.</li> </ul>				
		5. Blinatumomab should only be requested by and administered in principal treatment centres				
Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patient	6. The use of the blinatumomab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.	Yes	TA450	27-Apr-17	26-Sep-17
		7. The patient has a performance status of 0 - 2.				
		8. A maximum of 5 cycles of treatment with blinatumomab will be administered.				
		9. Blinatumomab will be used as monotherapy	1			
		10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		11. Trust policy regarding unlicensed treatments should be followed as blinatumomab is not licensed in this indication in children				
		12. Blinatumomab should otherwise be used as set out in its Summary of Product Characteristics (SPC).				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Bosutinib	Bosutinib for previously treated chronic myeloid leukaemia	<ol> <li>I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>I confirm the patient has chronic, accelerated or blast phase Philadelphia chromosome positive chronic myeloid leukaemia.</li> <li>I confirm the patient has had previous treatment with 1 or more tyrosine kinase inhibitor.</li> <li>I confirm that treatment is not appropriate with either imatinib, nilotinib or dasatinib.</li> </ol>	Yes	TA401	24-Aug-16	22-Nov-16
Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant in ADULT patients where the following criteria are met:	<ol> <li>I confirm the patient will receive the licensed dose and frequency of bosutinib</li> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has relapsed or refractory CD30+ Hodgkin lymphoma.</li> <li>The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant</li> <li>The patient has never received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-1</li> <li>Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</li> <li>The patient is an adult*         <ul> <li>*note there is a separate blueteq form to be used for brentuximab in this indication in children</li> </ul> </li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).</li> <li>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</li> <li>No re-use of brentuximab will be used outside this indication unless previous partial/complete response to brentuximab and</li> </ol>	Yes	TA446	28-Apr-17	26-Sep-17
		brentuximab is being used as a bridge to allogeneic stem cell transplant or donor lymphocyte infusion* *note there is a separate blueteq form for such re-use of brentuximab  9. A maximum of 16 cycles of brentuximab will be administered to the patient  10. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Brentuximab	Treatment of brentuximab-naïve relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant in CHILD patients where the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has relapsed or refractory CD30+ Hodgkin lymphoma.</li> <li>The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant</li> <li>The patient has never received brentuximab</li> <li>Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</li> <li>Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response</li> <li>The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002</li> <li>hother patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002</li> <li>http://www.bloodjournal.org/content/122/21/4378</li> <li>*note there is a separate Bluteq form to be used for brentuximab in this indication in adults.</li> <li>The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.</li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).</li> <li>*Requests for continuation of treatment after unp</li></ol>	Yes	TA446	28-Apr-17	26-Sep-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.				
		3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant				
		4. Previous use of brentuximab achieved a partial/complete response to brentuximab	-			
		5. Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion	]			
Brentuximab	Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma in	6. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response	Yes	TA446	28-Apr-17	26-Sep-17
	ADULT patients:	7. The patient is an adult* *note there is a separate blueteq form to be used for brentuximab in this indication in children				
		8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		9. A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab				
		10. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has relapsed or refractory CD30+ Hodgkin lymphoma.	_			
		3. The patient has relapsed Hodgkin lymphoma after autologous stem cell transplant				
		4. Previous use of brentuximab achieved a partial/complete response to brentuximab	-			
		5. Brentuximab is being used as a bridge to allogeneic stem cell transplantation or donor lymphocyte infusion				
		6. Treatment with brentuximab will be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response	e			
Duomtuuduook	Re-use of brentuximab in	7. The patient is a child* and is either post pubescent or is pre pubescent and will receive brentuximab dosage described in the phase 2 part of the brentuximab trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378	Vas			26 San 47
Brentuximab	CHILD patients:	*note there is a separate Bluteq form to be used for brentuximab in this indication in adults.	Yes	TA446	28-Apr-17	26-Sep-17
		8. The use of the brentuximab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.	t of			
		9. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process				
		10. A maximum of 16 cycles of brentuximab will be administered to the patient when combining this reuse and previous cycles of brentuximab				
		11. Trust policy regarding unlicensed treatments has been followed as brentuximab is not licensed in this indication in children.				
		12. Brentuximab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in ADULT patients, where the following criteria have been met:	1. An application has been made and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient has relapsed or refractory systemic anaplastic large cell lymphoma after front line chemotherapy Note: Brentuximab is not available for 1° cutaneous anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma  3. Histologically confirmed CD30 positive disease  4. The patient has never previously received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-2  5. Brentuximab is to be used as single-agent therapy  6. The patient has an ECOG performance status of 0-1  7. The patient is an adult Note: There is a separate blueteq form to be used for brentuximab in this indication in children  8. Treatment with brentuximab to be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response  9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve) Note: Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process  10. A maximum of 16 cycles of brentuximab may be administered per patient  11. Brentuximab will be otherwise used as set out in its Summary of Product Characteristics	Yes	TA478	04-Oct-17	02-Jan-18
Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in CHILD patients, where the following criteria have been met:	1. An application has been made and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient has relapsed or refractory systemic anaplastic large cell lymphoma after front line chemotherapy Note: Brentuximab is not available for 1° cutaneous anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma unless it has transformed into systemic anaplastic large cell lymphoma  3. Histologically confirmed CD30 positive disease  4. The patient has never previously received brentuximab unless previously enrolled in the NCRI-adopted clinical trial called ECHELON-2  5. Brentuximab is to be used as single-agent therapy  6. The patient has an ECOG performance status of 0-1  7. The patient has an ECOG performance status of 0-1  7. The patient is a child* and either post pubescent or is pre pubescent and will receive brentuximab vedotin dosage as described in phase 2 of the trial protocol C25002 http://www.clinicaltrials.gov/ct2/show/NCT01492088?term=C25002&rank=1 and reported on http://www.bloodjournal.org/content/122/21/4378  Note: there is a separate Blueteq form to be used for brentuximab vedotin in this indication in adults  8. The use of brentuximab in this setting and in this patient has been discussed at a multi-disciplinary team (MDT) meeting which must include at least 2 consultants in the subspecialty with active and credible expertise in the relevant field of whom one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area  9. Treatment with brentuximab to be discontinued after 4 cycles if CT or PET-CT scans to assess response demonstrate a response status of less than a partial or a complete response  10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurre	Yes	TA478	04-Oct-17	02-Jan-18

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
		2. I confirm the patient has hormone-relapsed metastatic prostate cancer.			25-May-16	
Cabazitaxel	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel	3. I confirm the patient has received 225mg/m/sq or more of docetaxel and the disease has progressed during or after docetaxel chemotherapy.	Yes	TA391		25-May-16
		4. I confirm cabazitaxel is to be prescribed in combination with prednisone or prednisolone.	1			
		5. I confirm the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.				
		6. I confirm the patient has been informed that treatment with cabazitaxel will be stopped if the disease progresses or after a maximum of 10 cycles (whichever happens first).				
		7. I confirm the licensed dose and frequency of cabazitaxel will be used.	1			
		<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has a histological diagnosis of renal cell carcinoma with a clear cell component</li> <li>The patient has either metastatic disease or inoperable locally advanced disease</li> <li>The patient has previously received at least 1 vascular endothelial growth factor (VEGF)-targeted systemic therapy for renal cancer and has not been previously treated with cabozantinib</li> <li>The patient has progressed on previous treatment or within 6 months of most recent dose of VEGF inhibitor</li> </ol>				
	The treatment of previously treated	6. The patient has a performance status of 0 or 1  7. If the patient has brain metastases then these have been treated and are stable	-			1
Cabozantinib	advanced renal cell carcinoma where the following criteria are met:	8. Cabozantinib is to be continued until disease progression or unacceptable toxicity or the patient's choice to stop treatment	Yes	TA463	08-Nov-17	08-Nov-17
		9. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment				
		10. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*  *Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment				
		break approval process.  11. Cabozantinib will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. This application is made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. This patient has a confirmed histological diagnosis of medullary thyroid carcinoma				
		3. The patient has either metastatic disease or inoperable locally advanced disease			28-Mar-18	26-Jun-18
	The treatment of medullary thyroid cancer where all the following criteria are met:	4. The disease is progressive and is either symptomatic or imminently likely to become symptomatic	]			
		5. The patient is treatment naïve to both cabozantinib and vandetanib unless the patient has had to discontinue vandetanib within 3 months of starting vandetanib because of toxicity (ie there is vandetanib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on vandetanib		Yes TA516		
Cabozantinib		Note: The sequential use of cabozantinib and then vandetanib is only funded if the patient has to discontinue cabozantinib because of intolerance within 3 months of its start and if the disease has not progressed whilst the patient is on cabozantinib. The use of vandetanib after disease progression on or after cabozantinib is not funded and vice versa	;e Yes			
		6. The patient has an ECOG performance status of 0 or 1 or 2.	1			
		7. Cabozantinib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment				
		8. A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment				
		9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		10. Cabozantinib is to be otherwise used as set out in its Summary of Product Characteristics				
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy		TA475		17-Oct-17
		2. The patient has a diagnosis of multiple myeloma.	nt Yes			
		<ul><li>3. The patient has relapsed or progressing disease.</li><li>4. The patient has only received one line of prior treatment for myeloma (induction chemotherapy, followed by stem cell transplant</li></ul>				
	The treatment of previously treated	is considered to be 1 line of therapy)				
Carfilzomib	multiple myeloma where all the following	5.The patient has received no prior treatment with Bortezomib.			19-Jul-17	
	crtieria are met:	6. I confirm that the patient has a performance status (PS) 0 - 2.	]			
		7. Carfilzomib will only be administered in combination with dexamethasone and no other systemic anticancer therapies (SACT).				
		8. No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*				
		9. Carfilzomib will otherwise be used as set out in its Summary of Product Characteristics (SPC).				
		1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.	No TA395			20-Sep-16
Ceritinib	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell	2. I confirm the patient has a confirmed diagnosis (either histologically or cytologically) of stage IIIB or IV NSCLC that carries an ALK rearrangement.		TA395	22-Jun-16	
	lung cancer	3. I confirm that the patient has been previously treated with crizotinib and the disease has progressed during or after therapy. Ceritinib is not funded for use following previous ALK inhibitor therapy other than with crizotinib.				
		4. I confirm the licensed dose and frequency of ceritinib will be used.				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ceritinib	The first line treatment of anaplastic lymphoma kinase-positive advanced nonsmall-cell lung cancer	1. The application is made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient has a histologically or cytologically confirmed diagnosis of stage IIIB or IV non small cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement  3. The patient has received no previous ALK-targeted therapy  4. The patient has received no previous cytotoxic chemotherapy for locally advanced or metastatic non small cell lung cancer ie no previous systemic treatment except when this has been given as neoadjuvant or adjuvant therapy or concurrently with radiotherapy  5. Ceritinib will be used only as single-agent therapy  6. The patient has an ECOG performance status of 0 or 1 or 2  7. The patient either has no brain metastases or, if the patient has brain metastases, the patient is symptomatically stable prior to starting ceritinib  8. The patient will be treated until loss of clinical benefit or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner  9. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle  10. Ceritinib will be otherwise used as set out in its Summary of Product Characteristics  11. In cases of intolerance to ceritinib, either alectinib or crizotinib is to be used only if the patient has not had progressive disease whilst on ceritinib. Neither alectinib or crizotinib after disease progression on ceritinib	No	TA500	24-Jan-18	24-Apr-18
Cetuximab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Metastatic colorectal cancer with no previous treatment for metastatic disease  3. RAS wild-type metastatic colorectal cancer  4. Cetuximab will be given in combination with Irinotecan-based combination chemotherapy  5. Cetuximab wil be given as a 2-weekly regimen at a dose of 500mg/m2  6. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below)  Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)  Note: If excessive toxicity with irinotecan, cetuximab can be continued with a fluoropyrimidine alone until disease progression only.  Note:  * Patients with potentially resectable metastatic disease who receive cetuximab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with cetuximab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug.  * Additionally patients who have successful resection(s) after neoadjuvant cetuximab may receive cetuximab with subsequent first-line treatment if they present later with advanced disease.  * Cetuximab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.		TA439	29-Mar-17	27-Jun-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started		
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy						
		2. Metastatic colorectal cancer with no previous treatment for metastatic disease						
		3. RAS wild-type metastatic colorectal cancer						
		4. Cetuximab will be given in combination with oxaliplatin-based combination chemotherapy						
		5. Cetuximab wil be given as a 2-weekly regimen at a dose of 500mg/m2						
Cetuximab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	6. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below).	Yes	TA439	29-Mar-17	27-Jun-17		
	Tollowing criteria are met.	Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)	e est-					
		Note:  * Patients with potentially resectable metastatic disease who receive cetuximab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with cetuximab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug.  * Additionally patients who have successful resection(s) after neoadjuvant cetuximab may receive cetuximab with subsequent first-line treatment if they present later with advanced disease.  * Cetuximab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.						
Cetuximab	The first line treatment of recurrent/metastatic oral cavity cancer where the following criteria are met:	<ol> <li>An application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>The patient has a confirmed histological diagnosis of squamous cell carcinoma.</li> <li>The patient has a primary tumour that originated in the oral cavity.</li> <li>The patient has recurrent and/or metastatic disease.</li> <li>The patient has not received any previous systemic chemotherapy for this oral cavity tumour unless it was part of multimodality treatment for locally advanced disease and was completed more than 6 months previously.</li> <li>Treatment will be given with palliative intent.</li> <li>Cetuximab is to only be used in combination with a maximum of 6 cycles of platinum-based combination chemotherapy followed by single agent cetuximab as maintenance therapy.</li> <li>The patient has received no previous treatment with cetuximab for head and neck cancer.</li> </ol>	Yes	TA473	TA473	TA473	31-Aug-17	31-Aug-17
		<ul><li>9. The patient has a performance status of 0-1.</li><li>10. Cetuximab is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment, whichever is the sooner.</li></ul>						
		<ul> <li>11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).</li> <li>12. Consideration has been to be given to administration of cetuximab 500mg/m² every 2 weeks (e.g. if chemotherapy is scheduled and 4 week cycle or during the maintenance phase of single agent cetuvimab thorapy).</li> </ul>						
		on a 4 week cycle or during the maintenance phase of single agent cetuximab therapy).  13. Cetuximab will be otherwise used as set out in its Summary of Product Characteristics.	-					
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.						
	Crizotinib for untreated anaplastic	2. I confirm the patient has a histologically or cytologically conformed diagnosis of stage IIIB or IV nonsmall-cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement	1					
Crizotinib	lymphoma kinase-positive advanced non- small-cell lung cancer	3. I confirm the patient has had no previous 1st line systemic therapy (chemotherapy or other ALK inhibitors) for advanced or metastatic non-small cell lung cancer unless any NICE-approved 1st line ALK inhibitor therapy has had to be discontinued on account of unacceptable toxicity AND there is no evidence of disease progression	No TA406	TA406	.406 28-Sep-16	28-Dec-16		
		4. I confirm the patient will receive the licensed dose and frequency of crizotinib.						

Dabrafenib and Trametinib  Dasatinib  Dasatinib	rizotinib for previously treated anaplastic imphoma kinase-positive advanced non-mall-cell lung cancer rametinib in combination with abrafenib for treating unresectable or	<ol> <li>I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>I confirm the patient has a histologically or cytologically conformed diagnosis of stage IIIB or IV nonsmall-cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement</li> <li>I confirm this is a 2nd or subsequent line treatment post 1st line platinum based combination chemotherapy and that the patient has not previously been treated with another ALK inhibitor</li> <li>I confirm the patient will receive crizotinib as set out in its Summary of Product Characteristics</li> <li>I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a</li> </ol>	- No	TA422	21-Dec-16	started 21-Mar-17
Dabrafenib and Trametinib  Dasatinib  Dasatinib	rametinib for treating unresectable or	cell lung cancer that carries an anaplastic lymphoma kinase (ALK) rearrangement  3. I confirm this is a 2nd or subsequent line treatment post 1st line platinum based combination chemotherapy and that the patient has not previously been treated with another ALK inhibitor  4. I confirm the patient will receive crizotinib as set out in its Summary of Product Characteristics		TA422	21-Dec-16	21-Mar-17
Dabrafenib and Trametinib  Dasatinib  Dasatinib	rametinib in combination with abrafenib for treating unresectable or	has not previously been treated with another ALK inhibitor  4. I confirm the patient will receive crizotinib as set out in its Summary of Product Characteristics	_			
Trametinib and dab met  Dasatinib  Dasatinib	rametinib in combination with abrafenib for treating unresectable or					
Trametinib and dab met  Dasatinib  Dasatinib	rametinib in combination with abrafenib for treating unresectable or	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a				
Trametinib and dab met  Dasatinib  Dasatinib	abrafenib for treating unresectable or	consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.			96 22-Jun-16	
Dasatinib Das chro		2. I confirm the patient has a confirmed diagnosis, histologically, of stage III (unresectable) or stage IV melanoma with a BRAF V600 mutation only.	No	TA396		20-Sep-16
<b>Dasatinib</b> chro	etastatic melanoma	3. I confirm the licensed dose and frequency of dabrafenib and trametinib will be used*.  *The only exception to this is for patients enrolled in the NIHR-approved INTERIM trial where intermittent treatment is allowed can be given in the experimental arm				
<b>Dasatinib</b> chro		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
En 7:	Dasatinib for the treatment of untreated chronic phase chronic myeloid leukaemia	<ul> <li>2. I confirm that the patient has chronic phase myeloid leukaemia</li> <li>3. I confirm that the patient has received no prior treatment unless it was dasatinib received as part of the SPIRIT 2 trial for this indication and the patient meets all other criteria listed here*</li> <li>*In March 2018 patients previously entered into the Spirit 2 trial and receiving free-of-charge supplies of dasatinib can transition to NHS commercial supply.</li> </ul>	No	TA426	21-Dec-16	21-Mar-17
Fn7:		4 I confirm that imatinib is not appropriate for this patient and that this has been discussed and supported by the relevant MDT involved in CML decision making unless they are already receiving dasatinib as part of the SPIRIT 2 trial for this indication and the patient meets all other criteria listed here  5. I confirm that dasatinib will be used as outlined in the Summary of Product Characteristics (SPC).				
<b>Enzalutamide</b> hor	nzalutamide for treating metastatic ormone-relapsed prostate cancer before hemotherapy		Yes	TA377	27-Jan-16	26-Apr-16
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a				21-Dec-16
Erib	ribulin for treating locally advacned or	2. I confirm that the patient has advanced breast cancer				
	netastatic breast cancer after 2 or more	3. I confirm that the patient has has at least 2 prior chemotherapy regimens for advanced disease	Yes	TA423	21-Dec-16	
che	nemotherapy regimens	4. I confirm the licensed dose and frequency of eribulin will be used.				
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a				
	<b>1</b>	consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. I confirm that the patient has ER +ve, HER2 –ve metastatic breast cancer	+			
		3. I confirm that the patient has no symptomatic visceral disease	†			
	verolimus with exemestane for treating	4. I confirm that everolimus will be given in combination with exemestane	- -	TA 424	24.5 46	24 D 46
	dvanced breast cancer after endocrine	5. I confirm that the patient has had previous treatment with a non-steroidal aromatase inhibitor	Yes	TA421	21-Dec-16	21-Dec-16
tnei	nerapy	6. I confirm that the patient has had no previous treatment with exemestane for metastatic breast cancer	]			
		7. I confirm that the patient has had no more than one line of chemotherapy for the treatment of advanced breast cancer	1			
		7. I confirm the licensed dose and frequency of everolimus will be used.				
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a				
	<b>.</b>	consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy	1			23-May-17
Everolimus	Everolimus for advanced renal cell carcinoma after previous treatment	<ul><li>2. I confirm that the patient has biopsy proven renal cell carcinoma</li><li>3. I confirm that the patient has progressed during or after treatment with vascular endothelial growth factor targeted therapy</li></ul>	- Yes	TA432	22-Feb-17	
	arcinoma after previous treatment	1 1 0 0 12 1 12 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has histopathologically proven well differentiated neuroendocrine tumour of pancreatic origin</li> <li>The patient has unresectable or metastatic disease</li> <li>The patient has exhibited disease progression in past 12 months</li> <li>The patient has a performance status of 0-1</li> <li>The patient has had no previous treatment with a mTOR inhibitor.</li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</li> <li>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</li> <li>Everolimus will otherwise be used as set out in its Summary of Product Characteristics (SPC).</li> </ol>	Yes	TA449	13-May-17	26-Sep-17
Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of gastrointestinal or lung origin with disease progression where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has histopathologically proven well differentiated neuroendocrine tumour of gastrointestinal or lung origin</li> <li>The patient has unresectable or metastatic disease</li> <li>The patient has no history of and no active symptoms to suggest a functional tumour</li> <li>The patient has exhibited disease progression in past 12 months</li> <li>The patient has a performance status of 0-1</li> <li>The patient has had no previous treatment with a mTOR inhibitor.</li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</li> <li>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</li> <li>Everolimus will otherwise be used as set out in its Summary of Product Characteristics (SPC).</li> </ol>	Yes	TA449	13-May-17	26-Sep-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Ibrutinib	Ibrutinib for previously treated chronic lymphocytic leukaemia in patients failing to respond to chemoimmunotherapy OR having a progression-free interval of <3 years with the preceding treatment OR having a progression free interval of ≥3 years with the preceding treatment and comorbidities which contraindicate consideration of further chemoimmunotherapy where the following criteria are met:  NOTE: there is a separate form for the funding of ibrutinib in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy	<ul> <li>4. The patient is considered not appropriate for treatment or retreatment with chemoimmunotherapy for one of the reasons outlined below.</li> <li>Please indicate below whether this is due to one of the following;</li> <li>Failure to respond to preceding chemoimmunotherapy OR</li> <li>A progression-free interval of less than 3 years with the preceding line of therapy OR</li> <li>A progression-free interval of ≥3 years with the preceding line of therapy AND the presence of comorbidities which contraindicate consideration of chemoimmunotherapy</li> <li>NOTE: there is a separate form for the funding of ibrutinib in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy</li> <li>5. The patient has a performance status of ECOG 0-2</li> <li>6. The patient has a platelet count of ≥ 0.75 x 109/l unless due to underlying disease</li> <li>7. The patient has a platelet count of ≥ 30 x 109/l unless due to underlying disease</li> <li>8. The patient is not on warfarin or strong CYP3AM/5 inhibitors</li> </ul>	Yes	TA429	25-Jan-17	25-Apr-17
Ibrutinib	Ibrutinib for previously treated chronic lymphocytic leukaemia in patients with a progression-free interval of ≥3 years with the preceding treatment and who do not have comorbidities which contraindicate consideration of chemoimmunotherapy where the following criteria are met:  NOTE: there is a separate form for the funding of ibrutinib in patients failing to respond to chemoimmunotherapy OR having a progression-free interval of <3 years with the preceding treatment OR having a progression free interval of ≥3 years with the preceding treatment and who have comorbidities which contraindicate consideration of further chemoimmunotherapy	3. The patient has received at least one prior anti-CD20 - containing chemoimmunotherapy for CLL/SLL	Yes	TA429	25-Jan-17	25-Apr-17

v1.101 31 August 2018

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				otal ted
		2. The patient has Chronic lymphocytic leukaemia (CLL) or Small lymphocytic leukaemia (SLL) with a 17p deletion or TP53 mutation				
		3. The patient is not appropriate for chemo-immunotherapy	1			
	Ibrutinib for the treatment of chronic	4. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2				
Ibrutinib	lymphocytic leukaemia with 17p deletion	5. The patient has a neutrophil count of ≥0.75 x 10 <sup>9</sup> /l unless due to underlying disease	Yes	TA429	25-Jan-17	25-Apr-17
	or TP53 mutation	6. The patients has a platelet count of ≥30 x 10°/l unless due to underlying disease				
		7. The patient is not taking either warfarin or strong CYP3A4/5 inhibitors	1			
		8. The patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.	as			
		9. Ibrutinib will be used as outlined in the Summary of Product Characteristics (SPC).	1			
		1. The application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist				
		specifically trained and accredited in the use of systemic anti-cancer therapy.	_			
		2. The patient has a confirmed histopathological diagnosis of mantle cell lymphoma				
		3. The patient has been previously been treated with one prior line of rituximab-containing chemotherapy ONLY. Induction	1			
		chemotherapy followed by maintenance rituximab or induction chemotherapy followed by stem cell transplantation count as 1 line				
		4. Presence of relapsed/refractory mantle cell lymphoma with documented progression of disease during or following rituximab-containing 1st line chemotherapy				
	The treatment of relapsed or refractory mantle cell lymphoma in patients who	5. The patient has never received any B cell receptor therapies (ibrutinib or other Bruton's tyrosine kinase inhibitors)	Yes TA502			
Ibrutinib	have received only 1 prior line of systemic therapy where all the following criteria are met:	6. Ibrutinib is to be used as a single agent		TA502	31-Jan-18	01-May-18
		7. Ibrutinib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment				
		8. The patient's performance status is 0 or 1 or 2				
		9. The patient is not on concurrent therapy with warfarin or CYP3A4/5 inhibitors				
		10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		11. Ibrutinib will be otherwise used as set out in its Summary of Product Characteristics				
		1. I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
		2. I confirm the patient has stage III (unresectable) or stage IV histologically confirmed melanoma.	-			
		3. I confirm that the patient is of performance status (PS) 0 or 1.	-			
Ipilimumab and	Nivolumab in combination with	4. I confirm that the patient has not received previous treatment with any of anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody for metastatic disease.				
Nivolumab	ipilimumab for treating advanced melanoma  5 * m	5. I confirm that the patient has only received allowed prior systemic therapy*  *Allowed prior therapy is 1) prior adjuvant therapy with immune checkpoint inhibitors when given as part of a clinical trial either as monotherapy or in combination with ipilimumab and/or 2) BRAF/MEK inhibitor targeted therapies when given for advanced disease; prior adjuvant therapy with ipilimumab + nivolumab is not allowed	- No	No TA400	27-Jul-16	25-Oct-16
		6. I confirm the patient has no symptomatic brain metastases or leptomeningeal metastases currently requiring steroids for symptom control.				
		7. I confirm the licensed doses and frequencies of nivolumab and ipilimumab will be used.				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. The application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has a confirmed histological diagnosis of renal cell carcinoma with a clear cell component				
		3. The patient has either metastatic disease or inoperable locally advanced disease				
		4. The patient has previously received only 1 vascular endothelial growth factor (VEGF)-targeted systemic therapy for advanced/metastatic renal cancer*				
		5. The patient has progressed on previous treatment or within 6 months of discontinuing previous treatment				
		6. The patient has an ECOG performance status of either 0 or 1* *Patients with a performance status of 2 or more are not eligible for lenvatinib with everolimus				
Lenvatinib with	The treatment of previously treated	7. The patient has received no previous treatment with either lenvatinib or everolimus			24-Jan-18	
everolimus	advanced renal cell carcinoma	8. The patient either has no brain metastases or, if the patient has brain metastases, then these have been treated and are symptomatically stable	No	TA498		24-Apr-18
		9. Lenvatinib with everolimus will be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment				
		10. If unacceptable toxicity occurs, the daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/management plan as set out in section 4.2 of the Summary of Product Characteristics for lenvatinib (Kisplyx)				
		11. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		12.Lenvatinib (Kisplyx) and everolimus are to be otherwise used as set out in their Summaries of Product Characteristics				
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. Confirmed histological or cytological diagnosis of pancreatic adenocarcinoma				
		3. Patient must have metastatic disease (patients with locally advanced disease are ineligible)				
	The treatment of untreated metastatic	4. Patient has not received any previous systemic chemotherapy for the pancreatic cancer unless given as a radiosensitiser in the				
Nab-paclitaxel with	pancreatic cancer only if other	adjuvant setting and completed at least 6 months previously				
gemcitabine	combination chemotherapies are unsuitable and they would otherwise	5. Nab-paclitaxel is to be used only in combination with gemcitabine	No TA476	TA476	06-Sep-17	05-Dec-17
	have gemcitabine monotherapy	6. Nab-paclitaxel plus gemcitabine is to be used as 1 <sup>st</sup> line treatment only 7. Patient has a performance status of 0 or 1				
		8. Patient is not considered to be a suitable candidate for oxaliplatin- and irinotecan-based combination chemotherapy and would otherwise receive gemcitabine monotherapy				
		9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		10. Nab-paclitaxel to be otherwise used as set out in its Summary of Product Characteristics				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Nilotinib	Nilotinib for the treatment of untreated chronic phase chronic myeloid leukaemia	<ol> <li>I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>I confirm that the patient has chronic phase myeloid leukaemia</li> <li>I confirm that the patient has received no prior treatment</li> <li>I confirm that imatinib is not appropriate for this patient and that this has been discussed and supported by the relevant MDT involved in CML decision making</li> <li>I confirm that nilotinib will be used as outlined in the Summary of Product Characteristics (SPC).</li> </ol>	No	TA426	21-Dec-16	21-Mar-17
Nivolumab	The treatment of relapsed or refractory classical Hodgkin Lymphoma in ADULT patients where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The prescribing clinician is aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis  3. The patient has a histologically confirmed diagnosis of classical Hodgkin's Lymphoma  4. The patient has relapsed or refractory disease  5. The patient has received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as part of previous therapy for classical Hodgkin's Lymphoma  6. The patient has had prior treatment with brentuximab vedotin  7. The patient has an ECOG performance status (PS) 0-1  8. The patient is an adult*.  *note there is a separate Blueteq form to be used for nivolumab in this indication in children.  9. Nivolumab will be given as monotherapy.  10. The patient has no known central nervous system lymphoma.  11. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody unless received as part of the nivolumab EAMS programme for this indication and meeting all other criteria listed.	Yes	TA462	26-Aug-17	26-Aug-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The prescribing clinician is aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.				
		3. The patient has a histologically confirmed diagnosis of classical Hodgkin's Lymphoma				
		4. The patient has relapsed or refractory disease			26-Aug-17	
		5. The patient has received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as part of previous therapy for classical Hodgkin's Lymphoma				
		6. The patient has had prior treatment with brentuximab vedotin	Yes	-		
		7. The patient has an ECOG performance status (PS) 0-1				
Nivolumab	The treatment of relapsed or refractory classical Hodgkin Lymphoma in PAEDIATRIC patients where all the following criteria are met:	8. The patient is a child* and either post pubescent or is pre pubescent and will receive nivolumab dosage as described in the publication Blood 2016; 128: 5414 *note there is a separate Bluteq form to be used for nivolumab in this indication in adults.				26-Aug-17
		9. Nivolumab will be given as monotherapy.				
		10. The patient has no known central nervous system lymphoma.				
		11. Nivolumab will only be requested by and administered in principal treatment centres.				
		12. The use of the nivolumab has been discussed at a multi disciplinary team (MDT) meeting which must include at least two consultants in the subspecialty with active and credible expertise in the relevant field of whom at least one must be a consultant paediatrician. The MDT should include a paediatric pharmacist and other professional groups appropriate to the disease area.				
		13. I confirm that Trust policy regarding unlicensed treatments has been followed as nivolumab is not licensed in this indication in children.				
		14. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.				
		15. Nivolumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Nivolumab	Nivolumab for previously treated	<ol> <li>I confirm that an application has been made and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>I confirm the patient has advanced or metastatic histologically proven renal cell carcinoma with clear cell component.</li> </ol>	No	TA417	23-Nov-16	23-Dec-16
rendential	advanced renal cell carcinoma	<ul> <li>3. I confirm the patient has been previously treated with only 1 or 2 previous lines of antiangiogenic therapy</li> <li>4. I confirm the patient's Karnofsky performance status (KPS) is 70 or more.</li> <li>5. I confirm the patient will receive the licensed dose and frequency of nivolumab</li> </ul>				23 500 10
		This application is made by and the first cycle of obinituzumab in combination with chemotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. The patient has a confirmed histological diagnosis of grade 1-3a CD20-positive follicular lymphoma		TA513	21-Mar-18	
	alone (r  4. The p of at lea Follicula 1. Age: 2. Serui 3. Haen 4. Ann 5. Num cervical The treatment of untreated advanced  (include)	3. The patient has not previously received any of the following for treatment of lymphoma: chemotherapy alone, immunotherapy alone (rituximab, obinutuzumab) or chemotherapy in combination with immunotherapy (rituximab, obinutuzumab).				
Obinutuzumab		<ul> <li>4. The patient has been assessed according to the Follicular Lymphoma International Prognostic Index (FLIPI) and has scored a value of at least 2. Please indicate FLIPI score: Follicular Lymphoma International prognostic Index (FLIPI) scoring system  1. Age: if &lt; 60 years, score 0; if ≥ 60 years, score 1  2. Serum LDH: if in normal range, score 0; if raised above normal range, score 1  3. Haemoglobin level: if ≥ 120g/L, score 0; if &lt; 120g/L, score 1  4. Ann Arbor stage: if stage I or II, score 0; if stage III or IV, score 1  5. Number of involved nodal areas: if ≤ 4, score 0; if ≥ 5, score 1. Each of the following is considered a single nodal area: left cervical, right cervical, left axillary, right axillary, mediastinal (includes hilar, paratracheal and retrocrural areas), mesenteric (includes coeliac, splenic and portal areas), para-aortic (includes common iliac and external iliac areas), left inguinal (includes left femoral area), right inguinal (includes right femoral area), other (eg epitrochlear, popliteal areas)</li> </ul>	No en			19-Jun-18
		5. The patient has bulky stage II disease (>7cm) or stage III disease or stage IV disease. Patients with stage I disease or non-bulky stage II disease are not eligible for obinutuzumab				
		6. Obinutuzumab is to be given in combination with induction combination chemotherapy for either: a maximum of 6 cycles if given with bendamustine or a maximum 6 cycles if given with CHOP or maximum 8 cycles if given with CVP				
		7. On completion of induction chemotherapy in combination with obinutuzumab, only patients having at least a documented partial response to treatment will commence maintenance therapy with single agent obinutuzumab once every 2 months for a maximum of 2 years or until disease progression (whichever occurs first)				
		8. The patient has an ECOG performance status of 0, 1 or 2	]			
		9. A formal medical review as to whether treatment with obinutuzumab in combination with chemotherapy should continue or not will be scheduled to occur at least by the end of the third cycle of treatment	not			
		10. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		11. Obinutuzumab is to be otherwise used as set out in its Summary of Product Characteristics				

v1.101 31 August 2018

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Olaparib	Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinumbased chemotherapy	nca	No	TA381	27-Jan-16	26-Apr-16
	The treatment of hormone receptor- n positive, HER2-negative, locally advanced or metastatic breast cancer	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Histologically or cytologically documented oestrogen receptor positive and her-2 negative breast cancer</li> </ol>				
		3. I confirm that the patient has had no prior treatment with a CDK 4/6 inhibitor unless either ribociclib has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or palbociclib has been received as part of the compassionate use scheme and the patient meets all the other criteria			20-Dec-17	
		4. Metastatic breast cancer or locally advanced breast cancer not amenable to curative treatment				
		5. The patient is male or is female and either post-menopausal or if pre- or peri-menopausal has undergone ovarian ablation or suppression with LHRH agonist treatment	Yes	TA495		20-Mar-18
aromatase inhibitor)		6. No previous hormone therapy for locally advanced or metastatic disease i.e. is hormone therapy naïve for locally advanced/metastatic breast cancer. Previous hormone therapy with anastrazole or letrozole whether as adjuvant therapy or as neoadjuvant treatment is allowed as long as the patient has had a disease-free interval of 12 months or more since completing treatment with anastrazole or letrozole.				
		7. Palbociclib will only be given in combination with an aromatase inhibitor  8. Patients have an ECOG performance status of 0-2  9. Patients will be treated until progressive disease or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner				
		10. Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle				
		11. Palbociclib will be otherwise used as set out in its Summary of Product Characteristics (SPC)				

v1.101 31 August 2018

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Panitumumab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Metastatic colorectal cancer with no previous treatment for metastatic disease  3. RAS wild-type metastatic colorectal cancer  4. Panitumumab will be given in combination with Irinotecan-based combination chemotherapy  5. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below)  Note: No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)  Note: If excessive toxicity with irinotecan, panitumumab can be continued with a fluoropyrimidine alone until disease progression only.  Note:  * Patients with potentially resectable metastatic disease who receive panitumumab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with panitumumab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug.  * Additionally patients who have successful resection(s) after neoadjuvant panitumumab may receive panitumumab with subsequent first-line treatment if they present later with advanced disease.  * Panitumumab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.	Yes	TA439	29-Mar-17	27-Jun-17
Panitumumab	The treatment of previously untreated metastatic colorectal cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Metastatic colorectal cancer with no previous treatment for metastatic disease  3. RAS wild-type metastatic colorectal cancer  4. Panitumumab will be given in combination with oxaliplatin-based combination chemotherapy  5. No previous treatment with Cetuximab or Panitumumab. Note prior use with neoadjuvant intent is permitted (See notes below)  Note: No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent co-morbidities)  Note: If excessive toxicity with oxaliplatin, panitumumab can be continued with a fluoropyrimidine alone until disease progression only.  Note:  * Patients with potentially resectable metastatic disease who receive panitumumab with the intention of resection if the metastases become resectable, and who do not progress while on treatment with panitumumab, but who become unsuitable for surgery or have unsuccessful surgery may continue treatment with the same drug.  * Additionally patients who have successful resection(s) after neoadjuvant panitumumab may receive panitumumab with subsequent first-line treatment if they present later with advanced disease.  * Panitumumab is not approved as adjuvant treatment where resection is successful or in combination with 2nd line chemotherapy.	Yes	TA439	29-Mar-17	27-Jun-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Panobinostat	Panobinostat for treating multiple myeloma after at least 2 previous treatments	nca	No	TA380	27-Jan-16	26-Apr-16
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
	The treatment of PD-L1-positive non smal cell lung cancer after chemotherapy	2. The prescribing clinician is fully aware of the management of and the treatment modifications that may be required for immune-related adverse reactions due to anti-PD-L1 treatments including pneumonitis, colitis, nephritis, endocrinopathies and hepatitis.	or			
		3. The patient has a histologically- or cytologically-confirmed diagnosis of stage IIIB or IV non-small cell lung cancer (squamous or non-squamous).				
		4. The patient's tumour expresses PD-L1 (that is, with a tumour proportion score [TPS] ≥1%) by an approved and validated test.				
Pembrolizumab		5. The patient has progressed after treatment with at least two cycles of platinum-containing doublet chemotherapy for stage IIIB/IV disease AND a targeted treatment if they have an EGFR or ALK-positive tumour.		TA428	11-Jan-17	11-Feb-17
		6. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.				
		7. The patient has no active brain metastases or leptomeningeal metastases.				
		8. The patient has not received prior treatment with an anti-PD-1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) antibody.				
		9. Pembrolizumab will be stopped at 2 years of treatment or on disease progression* or unacceptable toxicity, whichever occurs first.				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
	Demotraved maintenance treatment	2. I confirm the patient has locally advanced or metastatic non-squamous non-small cell lung cancer			24-Aug-16	
Pemetrexed	Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for nonsquamous non-small-cell lung cancer (review of TA309)	<ul> <li>3. I confirm pemetrexed is to be given as maintenance therapy following 1st line induction chemotherapy with cisplatin and pemetrexed* which has not progressed immediately after 4 cycles of such chemotherapy.</li> <li>* The evidence for the use of maintenance pemetrexed following induction chemotherapy with the combination of pemetrexed and carboplatin has not been established and is therefore not approved</li> </ul>	Yes	TA402		24-Aug-16
		4. I confirm the patient's Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1 at the start of maintenance treatment.	-			
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  NOTE: The application should be made immediately prior to commencing pertuzumab when given with single agent docetaxel chemotherapy plus trastuzumab as part of sequential anthracycline/docetaxel regimen and not at the start of the anthracycline based component.				
		2. I confirm that pertuzumab treatment is being given with neoadjuvant intent.	No TA424		21-Dec-16	
		3. I confirm that the patient has T2-T4b and/or histologically/cytologically proven node positive disease and that the patient also had M0 disease.				
		4. I confirm the patient has HER2 3+ by IHC or FISH/CISH positive disease.				21-Mar-17
		5. I confirm the baseline LVEF is greater than or equal to 55%.				
	Danton and facilities are and in conta	6. I confirm there has been no prior treatment with chemotherapy or HER2 therapy for this breast cancer.				
Pertuzumab	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer	7. I confirm that ONE of the following applies to this patient: the patient will have a maximum of 4 cycles of pertuzumab if given with single agent docetaxel chemotherapy plus trastuzumab as part of sequential anthracycline/docetaxel regimen; OR the patient will have a maximum of 6 cycles of pertuzumab only if given with combination of docetaxel and carboplatin chemotherapy plus trastuzumab; OR the patient will have maximum of 4 cycles of pertuzumab only if given with the first 4 cycles of chemotherapy in either arm of the NIHR-approved ROSCO neoadjuvant trial.		TA424		
		8. I confirm that ONE of the following applies to this patient: pertuzumab is to be given in combination with docetaxel-containing chemotherapy plus intravenous trastuzumab*; OR the patient is enrolled in the NIHR-approved neoadjuvant trial where pertuzumab can be given with chemotherapy in either arm of the study.  *Trastuzumab should be given IV when given in combination with pertuzumab but trastuzumab may be given IV or sc when given as a single agent in the adjuvant phase.				
		9. I confirm the patient will receive the licensed dose and frequency of pertuzumab*.  *Pertuzumab is only to be given in combination with intravenous trastuzumab. The use of pertuzumab will not be funded if given with subcutaneous trastuzumab.  *If the patient has a severe allergic reaction to docetaxel and is re-challenged with docetaxel unsuccessfully, neoadjuvant chemotherapy with pertuzumab and intravenous trastuzumab can be completed with paclitaxel replacing the docetaxel				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Pertuzumab	The first line treatment of locally advanced or metastatic breast cancer where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Locally advanced or metastatic breast cancer</li> <li>HER2 3+ or FISH positive breast cancer</li> <li>ECOG PS 0 or 1</li> <li>Any adjuvant HER2 therapy should have been completed more than 12 months prior to metastatic diagnosis</li> <li>No prior treatment with chemotherapy or HER2 therapy for metastatic disease</li> <li>The patient will receive pertuzumab as first line treatment in combination with docetaxel and IV trastuzumab*</li> <li>*The use of pertuzumab is only funded when given with intravenous trastuzumab. Use of pertuzumab with subcutaneous trastuzumab will not be funded</li> <li>I confirm that pertuzumab will otherwise be used as set out in its Summary of Product Characteristics (SPC).*</li> <li>*If a patient commences 1st line treatment with docetaxel and has a severe allergic reaction to the docetaxel and is re-challenged with docetaxel unsuccessfully, chemotherapy with the combination of paclitaxel, pertuzumab and intravenous trastuzumab can be used but only in these specific circumstances.</li> <li>*Not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone.</li> </ol>	Yes	TA509	07-Mar-18	05-Jun-18
Pomalidomide	Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib	1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.  2. I confirm the the patient has multiple myeloma  3. I confirm the patients performance status (PS) is 0-2  4. I confirm the patient has previously received 3 lines of treatment with adequate trials of at least all of the following options of therapy: bortezomib, lenalidomide and alkylating agents  5. I confirm that the patient has refractory disease to previous line of treatment  6. I confirm that pomalidomide will be used as outlined in the Summary of Product Characteristics (SPC).	No	TA427	11-Jan-17	11-Apr-17
Ponatinib	The treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukaemia where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. The patient has chronic phase, accelerated phase or blast phase chronic myeloid leukaemia  3. The disease is resistant to dasatinib or nilotinib, or the patient cannot have dasatinib nor nilotinib and imatinib is not clinically appropriate, or the T315I gene mutation is present	Yes	TA451	13-Feb-17	26-Sep-17
Ponatinib	The treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has Philadelphia chromosome positive acute lymphoblastic leukaemia</li> <li>Imatinib is not clinically appropriate for the patient or the T315I gene mutation is present</li> </ol>	Yes	TA451	13-Feb-17	26-Sep-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.				
		2. I confirm that the patient has histologically or cytologically confirmed adenocarcinoma of the prostate who has hormone-refractory disease with two or more bone metastases detected on skeletal scintigraphy OR the patient has a high clinical suspicion of prostate cancer with a high PSA value (>100ng/ml) and who has hormone-refractory disease with two or more bone metastases detected on skeletal scintigraphy.			28-Sep-16	
		3. I confirm the patient has symptomatic bone metastases with regular use of analgesic medication or treatment with external-beam radiation therapy required for cancer related bone pain within the previous 12 weeks.				
		4. I confirm the patient has no known visceral metastases and no previous history of visceral spread.				
Radium-223	Radium-223 dichloride for treating hormone-relapsed prostate cancer with	5. I confirm the patient has no malignant lymphadenopathy that is more than 3cm in diameter.	Yes	TA412		28-Dec-16
	bone metastases	6. I confirm the patient's Performance Status is 0-2				
		7. I confirm the patient has no imminent or established spinal cord compression.				
		8. I confirm the patient has had no previous hemibody external radiotherapy or systemic radiotherapy with radioisotopes within the previous 24 weeks				
		9. I confirm that the patient has already had prior docetaxel OR docetaxel is contraindicated or the patient is not suitable for docetaxel				
		10. I confirm that a sufficient trial of treatment with abiraterone or enzalutamide has been given to relieve bone symptoms before consideration of radium-223.				
		11. I confirm that the use of radium-223 will be as per the Summary of Product Characteristics (SPC).				
		1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. Patient has histologically confirmed, metastatic or unresectable GIST				
	The treatment of previously treated	3. Patient has ECOG performance status (PS) 0-1				
Regorafenib	unresectable or metastatic	4. Patient has had disease progression on or intolerance to previous imatinib	Yes	TA488	15-Nov-17	14-Feb-18
	gastrointestinal stromal tumours where all the following criteria are met:	5. Patient has had disease progression on or intolerance to previous sunitinib	163	171700	15 1100 17	17 1 CO 10
		6. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		7. Regorafenib to be otherwise used as set out in its Summary of Product Characteristics				

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>Histologically or cytologically documented oestrogen receptor positive and her-2 negative breast cancer</li> <li>I confirm that the patient has had no prior treatment with a CDK 4/6 inhibitor unless either palbociclib has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or ribociclib has been</li> <li>Metastatic breast cancer or locally advanced breast cancer not amenable to curative treatment</li> <li>The patient is male or is female and either post-menopausal or if pre- or peri-menopausal has undergone ovarian ablation or suppression with LHRH agonist treatment</li> <li>No previous hormone therapy for locally advanced or metastatic disease i.e. is hormone therapy naïve for locally advanced/metastatic breast cancer. Previous hormone therapy with anastrazole or letrozole whether as adjuvant therapy or as neoadjuvant treatment is allowed as long as</li> <li>Ribociclib will only be given in combination with an aromatase inhibitor</li> <li>Patients have an ECOG performance status of 0-2</li> <li>Patients will be treated until progressive disease or excessive toxicity or patient choice to discontinue treatment, whichever is the sooner</li> <li>Treatment breaks of up to 6 weeks are allowed but solely to allow toxicities to settle</li> <li>Ribociclib will be otherwise used as set out in its Summary of Product Characteristics (SPC)</li> </ol>	1 400	TA496	20-Dec-17	20-Mar-18
Ruxolitinib	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis	nca	Yes	TA386	23-Mar-16	21-Jun-16

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
<b>Sorafenib</b>	The first line treatment of Child-Pugh A locally advanced or metastatic hepatocellular carcinoma where all of the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. ONE of the following applies to the patient: the patient has a confirmed histological diagnosis of hepatocellular carcinoma or a biopsy is deemed to be very high risk or technically not feasible in the patient AND the criteria below are met:  a. The decision not to biopsy has been made and documented by a specialist HCC MDM  b. The turnour meets the non-invasive diagnostic criteria of hepatocellular carcinoma*  c. Data is submitted as part of the ongoing Sorafenib Audit 2.  It is expected that OPTION 2 will only apply in exceptional circumstances and it should be noted that responses will be reviewed regularly to ensure that this is the case.  *EASL-EORTC Clinical Practice Guidelines: Management, Journal of Hepatology 2012 vol. 56 p 908–943. Non-invasive criteria can only be applied to cirrhotic patients and are based on imaging techniques obtained by 4-phase multidetector CT scan or dynamic contrast-enhanced MRI. Diagnosis should be based on the identification of the typical hallmark of HCC (hypervascular in the arterial phase with washout in the portal venous or delayed phases). While one imaging technique is required for nodules beyond 1 cm in diameter a more conservative approach with 2 techniques is recommended in suboptimal settings.  3. Patient must have either metastatic disease or locally advanced disease that is ineligible for or failed surgical or locoregional therapies  4. Patient has not received any previous systemic therapy for hepatocellular carcinoma  5. Patient must have Child-Pugh liver function class A  6. Patient has a performance status of 0-2  7. Sorafenib is to be used as a single agent  8. Sorafenib is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment therapy to settle or intercurrent comorbidities to improve)  10. Sorafe	Yes	TA474	06-Sep-17	05-Dec-17
Sunitinib	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression where all the following criteria are met:	<ol> <li>An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy</li> <li>The patient has histopathologically proven well differentiated neuroendocrine tumour of pancreatic origin</li> <li>The patient has unresectable or metastatic disease</li> <li>The patient has exhibited disease progression in past 12 months</li> <li>The patient has a performance status of 0-1</li> <li>The patient has had no previous treatment with a tyrosine kinase inhibitor.</li> <li>No planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).*</li> <li>*Requests for continuation of treatment after unplanned treatment breaks over this duration should be made via the treatment break approval process</li> <li>Sunitinib will otherwise be used as set out in its Summary of Product Characteristics (SPC).</li> </ol>	Yes	TA449	13-May-17	26-Sep-17

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
		1. I confirm that an application has been made and the first treatment will be prescribed and administered by a consultant specialist experienced in the treatment of melanoma				
		2. I confirm this treatment will be given by a specialist trained to give intra-lesional injections of talimogene.				
	3. I confirm the patient has cutaneous, subcutaneous or nodal deposit(s) of melanoma which is/are suitable for direct injecti is/are not surgically resectable.					
		4. I confirm the patient has stage IIIb, stage IIIc or stage IVM1a disease according to the AJCC stage criteria of 2009 7th edition and if stage IVM1a disease (ie metastases to the skin, subcutaneous tissues or distant lymph nodes) has a normal serum LDH.				
Talimogene	Talimogene laherparepvec for treating	5. I confirm the patient has no bone, brain, lung or any other visceral secondaries and if stage IVM1a disease, the serum LDH is not elevated.	-			
Laherparepvec	unresectable metastatic melanoma	6. I confirm talimogene has been sanctioned by a specialist melanoma multidisciplinary team which includes an oncologist and a surgeon with expertise in the management of metastatic and locally advanced melanoma, respectively.	No	TA410	28-Sep-16	28-Dec-16
		7. I confirm that talimogene is appropriate for this patient as systemically administered immunotherapies or approved targeted therapies are not considered the best option by the specialist melanoma multidisciplinary team meeting which includes an oncologist and a surgeon with expertise in the management of metastatic and locally advanced melanoma, respectively.				
		8. I confirm that talimogene will only be administered as a single agent and not in combination with systemic therapies eg chemotherapy, targeted agents or immunotherapy unless this is within the context of a Health Research Authority clinical trial.				
		9. I confirm the patient will receive the licensed dose and frequency of talimogene laherparepvec				
		1. This application is made by and the first cycle of systemic anti-cancer therapy with tivozanib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy				
		2. This patient has a confirmed histological diagnosis of renal cell carcinoma with a clear cell component				
		3.The patient has either metastatic disease or inoperable locally advanced disease				
		4. The patient is treatment naïve to systemic therapy and in particular has previously received neither any vascular endothelial growth factor (VEGF)-targeted systemic therapy nor mTOR pathway inhibitor-targeted treatment unless prior treatment with pazopanib or sunitinib has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of progression (see criteria 10).				
		5. The patient has an ECOG performance status of either 0 or 1. A patient with a performance status of 2 is not eligible for tivozanib	-			
Tivozanib	The treatment of advanced renal cell	6. If the patient has brain metastases, then these have been treated and are stable	No	TA512	21-Mar-18	19-Jun-18
TIVOZATIID	carcinoma where all the following criteria are met:	7. Tivozanib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment	INO	14512	21-IVId1-10	19-Juli-10
		8. A formal medical review as to whether treatment with tivozanib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment	tle			
		9. No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)				
		10. I confirm that the patient has had no prior treatment either with pazopanib or sunitinib unless such prior treatment has had to be stopped solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression*.  *Patients treated with tivozanib may switch to pazopanib or sunitinib where treatment has had to be stopped early under the same circumstances.				
		11. Tivozanib is to be otherwise used as set out in its Summary of Product Characteristics	]			

Drug	NICE Approved Indication	Blueteq Approval Criteria	Previous CDF drug/ indication	TA	Date of Final NICE Guidance	Date baseline funding started
Trastuzumab Emtansine	The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer where all the following criteria are met:	1. An application has been made by and the first cycle of systemic anti-cancer therapy is to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy  2. Progression of her-2 positive locally advanced or metastatic breast cancer  3. Progression during or after the most recent treatment for advanced stage disease or within 6 months of completing treatment for early stage disease  4. Previous treatment with a taxane  5. Previous treatment with trastuzumab  6. Perfomance statau of 0, 1 or 2  7. Left ventricular ejection fraction of 50% or more  8. NOTE: not to be used beyond first disease progression outside the CNS. Do not discontinue if disease progression is within the CNS alone  9. no planned treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve).  10. will otherwise be used as set out in its Summary of Product Characteristics (SPC).  Note: To minimise the risk of errors due to the similarity of the product name Trastuzumab Emtansine (Kadcyla) with that of Trastuzumab the recommendations in the Risk Minimisation Plan educational material from the manufacturer should be followed when prescribing, dispensing and administering the product	Yes	TA371	19-Jul-17	17-Oct-17
Trifluridine- tipiracil	Trifluridine–tipiracil for previously treated metastatic colorectal cancer	<ol> <li>I confirm that an application has been made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.</li> <li>I confirm the patient has metastatic colorectal cancer.</li> <li>I confirm that the patient has failed at least two prior regimens* for advanced/metastatic disease. Those patients relapsing during or within 6 months of completing adjuvant chemotherapy can count the adjuvant line as one line of therapy for advanced/metastatic disease.</li> <li>* Prior regimens: fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents.</li> <li>I confirm that the patient is not considered a candidate for all other available therapies.</li> <li>I confirm that the patient has a PS 0 or 1.</li> <li>I confirm the patient will receive the licensed dose and frequency of trifluridine-tipiracil</li> </ol>	No	TA405	24-Aug-16	22-Nov-16

#### **Version Control**

Version No.Date publishedAuthor(s)Revision summary0.1n/aD Thomson; P ClarkInitial draft of new CDF list, based on pre-existing national CDF list but updated for changes to the CDF, for review.1.029-Jul-16D Thomson; P ClarkNew addition to CDF list1.109-Aug-16P ClarkNew addition to CDF list and revision of criteria for a number of existing drugs1.218-Aug-16D Thomson; P ClarkNew addition to CDF list and revision of criteria for a number of existing drugs1.324-Aug-16D Thomson; P ClarkRemoval of one drug/indication for baseline funding and date for baseline funding added for existing drugs.1.402-Sep-16D Thomson; P ClarkUpdate to Radium criteria and timeline following publication of NICE FAD1.520-Sep-16D Thomson; P ClarkRemoval of two drugs/indications for baseline funding1.627-Sep-16D Thomson; P ClarkRemoval of two drug indications1.704-Oct-16D Thomson; P ClarkAddition of new CDF drug and date for baseline funding added for existing drugs1.821-Oct-16D Thomson; P ClarkNew addition to CDF list1.925-Oct-16D Thomson; P ClarkNew addition to CDF list1.1003-Nov-16D Thomson; P ClarkUpdate to eviclining following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"1.1110-Nov-16D Thomson; P ClarkUpdate to everolimus following publication of NICE FAD; update to desatinib criteria following publication of NICE FAD1.121	
1.0 29-Jul-16 D Thomson; P Clark Final version of new CDF list 1.1 09-Aug-16 P Clark New addition to CDF list 1.2 18-Aug-16 D Thomson; P Clark New addition to CDF list and revision of criteria for a number of existing drugs 1.3 24-Aug-16 D Thomson; P Clark Removal of one drug/indication for baseline funding and date for baseline funding added for existing drugs. 1.4 02-Sep-16 D Thomson; P Clark Update to Radium criteria and timeline following publication of NICE FAD 1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding 1.6 27-Sep-16 D Thomson; P Clark Removal of two drug indications 1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs 1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list 1.9 25-Oct-16 D Thomson; P Clark Removal of two drug indication for baseline funding. 1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD 1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.1 09-Aug-16 P Clark New addition to CDF list 1.2 18-Aug-16 D Thomson; P Clark New addition to CDF list and revision of criteria for a number of existing drugs 1.3 24-Aug-16 D Thomson; P Clark Removal of one drug/indication for baseline funding and date for baseline funding added for existing drugs. 1.4 02-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding publication of NICE FAD 1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding 1.6 27-Sep-16 D Thomson; P Clark Removal of two drugs indications 1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs 1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list 1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding. 1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD 1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD: 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.2 18-Aug-16 D Thomson; P Clark Removal of one drug/indication for baseline funding and date for baseline funding added for existing drugs.  1.4 02-Sep-16 D Thomson; P Clark Update to Radium criteria and timeline following publication of NICE FAD  1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding  1.6 27-Sep-16 D Thomson; P Clark Removal of two drugs/indications  1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs  1.8 21-Oct-16 D Thomson; P Clark New addition to CDF Iist  1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding.  1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD  1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD:  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.3 24-Aug-16 D Thomson; P Clark Removal of one drug/indication for baseline funding and date for baseline funding added for existing drugs.  1.4 02-Sep-16 D Thomson; P Clark Update to Radium criteria and timeline following publication of NICE FAD  1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding  1.6 27-Sep-16 D Thomson; P Clark Removal of two drug indications  1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs  1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list  1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding.  1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD  1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.4 02-Sep-16 D Thomson; P Clark Update to Radium criteria and timeline following publication of NICE FAD  1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding  1.6 27-Sep-16 D Thomson; P Clark Removal of two drug indications  1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs  1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list  1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding.  1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD  1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.5 20-Sep-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding 1.6 27-Sep-16 D Thomson; P Clark Removal of two drug indications 1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs 1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list 1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding. 1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD 1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016" 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.6 27-Sep-16 D Thomson; P Clark Removal of two drug indications 1.7 04-Oct-16 D Thomson; P Clark Addition of new CDF drug and date for baseline funding added for existing drugs 1.8 21-Oct-16 D Thomson; P Clark New addition to CDF list 1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding. 1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD 1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016" 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.704-Oct-16D Thomson; P ClarkAddition of new CDF drug and date for baseline funding added for existing drugs1.821-Oct-16D Thomson; P ClarkNew addition to CDF list1.925-Oct-16D Thomson; P ClarkRemoval of one drug/indication for baseline funding.1.1003-Nov-16D Thomson; P ClarkUpdate to eribulin following publication of NICE FAD1.1110-Nov-16D Thomson; P ClarkUpdate to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"1.1217-Nov-16D Thomson; P ClarkTwo new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.821-Oct-16D Thomson; P ClarkNew addition to CDF list1.925-Oct-16D Thomson; P ClarkRemoval of one drug/indication for baseline funding.1.1003-Nov-16D Thomson; P ClarkUpdate to eribulin following publication of NICE FAD1.1110-Nov-16D Thomson; P ClarkUpdate to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"1.1217-Nov-16D Thomson; P ClarkTwo new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.9 25-Oct-16 D Thomson; P Clark Removal of one drug/indication for baseline funding.  1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD  1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.10 03-Nov-16 D Thomson; P Clark Update to eribulin following publication of NICE FAD  1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"  1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.11 10-Nov-16 D Thomson; P Clark Update to everolimus following publication of NICE FAD; update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016" 1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
1.12 17-Nov-16 D Thomson; P Clark Two new addition to CDF list and update to dasatinib criteria following publication of NICE FAD	
TITLE STATE TO THE STATE OF THE	
1.14 O2-Dec-16 D Thomson; P Clark New addition to CDF list (PEMB1_v1.0); update to neoadjuvant pertuzumab (PER2) criteria.	
1.15 12-Dec-16 D Thomson; P Clark New addition to CDF list (IBR3_v1.0); update to ibrutinib in pretreated CLL (IBR1) criteria.	
1.16 21-Dec-16 D Thomson; P Clark Removal of two drugs/indications for baseline funding; update of five timelines following publication of final NICE guidance; update to pembrolizumab criteria.	
1.17 23-Dec-16 D Thomson; P Clark Removal of one drug/indication for baseline funding; update to pertuzumab criteria	
1.18 28-Dec-16 D Thomson; P Clark Removal of three drugs and indications for baseline funding; removal of pegaspargase.	
1.19 12-Jan-17 D Thomson; P Clark Update to everolimus (RCC) following publication of NICE FAD; update to two timelines following publication of final NICE guidance; update to radium 223 criteria in sect	tion B
1.20 10-Feb-17 D Thomson; P Clark	CIOTE
Update to section B - "NICE approved and baseline funded drugs/indications from 1st April 2016"; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication of final NICE guidance; update of 2 timelines following publication o	date to popatinih following ACD
1.21 O2-Mar-17 D Thomson; P Clark Updates to section A - CET1, CET4, PAN3, PAN1. Updates to section B - Ipilimumab + Nivolumab, Dabrafenib + Trametinib	ate to pollatinis following ACD
1.22 21-Mar-17 D Thomson; P Clark Removal of 5 drugs/indications for routine funding and addition to section B. Update to Ipilimumab + Nivolumab criteria.	
1.23 11-Apr-17 D Thomson; P Clark Removal of 1 drugs/indications for routine funding .  Removal of 1 drugs/indications for routine funding .	
1.24 27-Apr-17 D Thomson; P Clark Removal of 2 drug/indications for routine funding and update to section B. Addition of two drug/indications following publication of FAD	
1.25 28-Apr-17 D Thomson; P Clark Following publication of ponatinib in CML FAD - incorporation of 2 previous separate sets of criteria into a single set  1.26 28 May 17 Paragon P Clark Population of ponatinib in CML FAD - incorporation of 2 previous separate sets of criteria into a single set	
1.26 02-May-17 D Thomson; P Clark Replacement of current criteria for brentuximab in HD with new criteria following publication of NICE FAD and update to blimautmomab in children criteria	
1.27 12-May-17 D Thomson; P Clark Addition of 2 CDF drug/indications and updated of 1 CDF drug/indication following publication of FAD  1.29 21 May 17 D Thomson; P Clark Persons B Clark Persons of 1 drug/indication for routing funding and 1 now drug/indication addition following publication of the FAD	
1.28 31-May-17 D Thomson; P Clark Removal of 1 drug/indication for routine funding and 1 new drug/indication addition following publication of the FAD	
1.29 02-Jun-17 D Thomson; P Clark 2 new drug/indications following publication of FAD  1.20 02-Jun-17 D Thomson; P Clark 2 new drug/indications following publication of 3 FADs, undetects existing criteria	
1.30 09-Jun-17 D Thomson; P Clark 3 new drug/indications following publication of 2 FADs; update to existing criteria  1.31 P. Creves P. Clark Project Services P. Clark Project Services and Project	
1.31 15-Jun-17 B Groves; P Clark Revision to 1 drug/indication following publication of FAD 1.32 30-Jun-17 D Thomson; B Groves Revision to 1 drug/indication in CDF / two drugs in 4 indications moved from CDF to routine commissioning	
1.33 10-Jul-17 P Clark; B Groves 1 new drug/indication following publication of FAD  1.34 P Clark D Thomson P Groves 1 new drug/indication; two drugs entering baseling commissioning, undate to OLA2, v1.1 interim funding status	
1.34 24-Jul-17 P Clark; D Thomson; B Groves 1 new drug/indication; two drugs entering baseline commissioning, update to OLA2_v1.1 interim funding status  1.35 OA Aug 17 P Clark: D Thomson: B Groves 1 new drug/indication for interim funding before moving into routing commissioning	
1.35 04-Aug-17 P Clark; D Thomson; B Groves 1 new drug/indication for interim funding before moving into routine commissioning  1.36 09 Aug 17 P Clark: D Thomson: P Groves 1 drug/indication revised and 1 new drug indication added	
1.36 08-Aug-17 P Clark; D Thomson; B Groves 1 drug/indication revised and 1 new drug indication added	sioning
1.37 10-Aug-17 P Clark; D Thomson; B Groves 1 drug/indication revised and 1 new drug indication added; update to treatment break criteria throughout; update to 1 drug with date for transition to routine commiss 24 Aug 17	
1.38 24-Aug-17 P Clark; B Groves 1 indication deleted and replaced with updated and separate child and adult treatment criteria; Removal of 1 drug/indication for routine funding and update to section	i b, z urugs available to flew patients status
1.39 31-Aug-17 D Thomson; B Groves 1 indication moved into routine commissioning; 1 indication updated to reflect notice period for registering new patients  1.40 D Thomson; B Groves 2 indications updated to reflect the date they may into routine commissioning; 1 indication updated to reflect notice period for registering new patients	
1.40 06-Sep-17 D Thomson; B Groves 2 indications updated to reflect the date they move into routine commissioning; 1 indication updated to reflect notice period for registering new patients	
1.41 08-Sep-17 P Clark; D Thomson; B Groves 1 new drug in 2 indications added; 1 existing indication updated to reflect expected entry into routine commissioning	
1.42 26-Sep-17 P Clark; D Thomson; B Groves 11 indications moved from CDF to routine commissioning	
1.43 28-Sep-17 P Clark; D Thomson; B Groves 1 drug/indication added	
1.44 05-Oct-17 P Clark; D Thomson; B Groves 1 drug/indication removed; 2 new CDF indications added	
1.45 12-Oct-17 P Clark; D Thomson 1 drug/indication revised following interim funding  1.46 P Clark D Thomson 1 drug/indication revised following interim funding	
1.46 13-Oct-17 P Clark; D Thomson 1 new drug/indication entering CDF  1.47 P Clark D Thomson 2 drugs/indications maying from CDF to resulting commissioning	
1.47 17-Oct-17 P Clark; D Thomson; B Groves 2 drugs/indications moving from CDF to routine commissioning	
1.48 01-Nov-17 P Clark; D Thomson; B Groves 1 drug/indication criteria updated	
1.49 05-Nov-17 P Clark; D Thomson; B Groves 1 drug/indication criteria removed	
1.50 08-Nov-17 P Clark; D Thomson; B Groves 1 drug/indication moved from CDF into routine commissioning	
1.51 16-Nov-17 P Clark; D Thomson; B Groves 2 new drug/indications added following publication of FAD	
1.52 22-Nov-17 P Clark; D Thomson; B Groves Notice of removal for 1 drug/indication; treatment criteria clarified for 1 drug/indication; 2 drug/indication titles amended	
1.53 05-Dec-17 P Clark; D Thomson; B Groves 2 drugs/indications moved into routine commissioning;	

v1.101 31 August 2018

#### **Version Control(Cont)**

Version No.	Date published	Author(s)	Revision summary
1.54	07-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication with interim funding
1.55	08-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication with interim funding
1.56	14-Dec-17	P Clark; D Thomson; B Groves	1 drug/indication split into two indications; 2 drugs/indication updated with dates for expected entry into routine commissioning
1.57	19-Dec-17	P Clark; D Thomson; B Groves	1 new CDF drug/indication; notice given for 2 drugs/indications attracting interim funding which will move into rountine commissioning in 90-days; 4 updates to criteria (1 CDF, 3 routine)
1.58	02-Jan-18	P Clark; D Thomson	2 drug/indications moving from CDF to routine commissioning; 4 updates to criteria (1CDF, 3 routine); 1 update to IFA section
1.59	17-Jan-18	P Clark: B Groves	1 drug/indication added to the CDF; 1 drug/indication updated
1.60	18-Jan-18	P Clark; D Thomson; B Groves	1 drug/indication updated
1.61	22-Jan-18	B Groves	1 drug/indication delisted
1.62	01-Feb-18	B Groves	3 drugs for 4 indications upated following NICE final guidance
1.63	09-Feb-18	P Clark; D Thomson; B Groves	1 drug/indication for routine commissioning
1.64	12-Feb-18	P Clark; D Thomson; B Groves	1 drug/indication for routine commissioning
1.65	15-Feb-18	P Clark; D Thomson; B Groves	3 drug/indication for routine commissioning which will receive interim CDF funding; 1 drug/indication moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.66	21-Feb-18	B Groves	2 drug/indications updated
1.67	01-Mar-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF; 1 drug/ indication for routine commissioning which will receive interim CDF funding; 3 drug/indications with updated treatment criteria
1.68	07-Mar-18	D Thomson; D Dwyer	1 indication moved into routine commissioning
1.69	16-Mar-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.70	20-Mar-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.71	21-Mar-18	D Thomson; D Dwyer	2 drugs/indications updated to reflect the date they move into routine commissioning
1.72	28-Mar-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning; 1 drug/indication moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.73	03-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication removed
1.74	09-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding
1.75	11-Apr-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning
1.76	19-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication with updated treatment criteria
1.77	24-Apr-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.78	25-Apr-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.79	27-Apr-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.80	01-May-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.81	04-May-18	P Clark; D Thomson; D Dwyer	5 drugs/indications which will receive interim CDF funding; 2 drugs/indications for routine commissioning
1.82	16-May-18	D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning
1.83	17-May-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding
1.84	25-May-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.85	01-Jun-18	P Clark; D Thomson; D Dwyer	1 drug/indication added to the CDF
1.86	05-Jun-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.87	13-Jun-18	P Clark; D Thomson; D Dwyer	8 drugs/indications updated to reflect the date they move into routine commissioning; 2 drugs/indications updated to note EMA recommendation; 1 drug/indication with updated treatment criteria
1.88	19-Jun-18	D Thomson; D Dwyer	2 drugs/indications moved into routine commissioning
1.89	26-Jun-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.90	28-Jun-18	P Clark; D Thomson; D Dwyer	1 drug/ indication for routine commissioning which will receive interim CDF funding; 1 drug/indication with updated treatment criteria
1.91	05-Jul-18	D Thomson; D Dwyer	2 drugs/indications with updated treatment criteria
1.92	10-Jul-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning
1.93	12-Jul-18	P Clark; D Thomson; D Dwyer	2 drugs/ indications for routine commissioning which will receive interim CDF funding; 3 drugs/indications moved into routine commissioning; 1 drug/indication with updated treatment criteria
1.94	13-Jul-18	D Thomson; D Dwyer	1 drug/indication moved into routine commissioning;
1.95	20-Jul-18	P Clark; D Thomson; D Dwyer	1 drug/indication updated to reflect the date it moves into routine commissioning; 1 drug/ indication for routine commissioning which will receive interim CDF funding; 1 drug/indication with updated treatment criteria
1.96	25-Jul-18	P Clark; D Thomson; B Groves	1 drug in 2 indications entering a CDF managed access period
1.97	03-Aug-18	D Thomson; D Dwyer	1 drug/indication with updated treatment criteria
1.98	09-Aug-18	P Clark; D Thomson; D Dwyer	2 drugs/indications for routine commissioning which will receive interim CDF funding; 2 drugs/indications with updated treatment criteria; 3 drugs/indications updated to reflect the date they move into routine commissioning
1.99	14-Aug-18	B Groves; P Clark; D Thomson	1 drug/indication moved into routine commissioning; 1 drug/indication moved back to the CDF list
	21,148 20		1 drug/indication for routine commissioning which will receive interim CDF funding; 3 drugs/indications with updated treatment criteria; 2 drugs/indications updated to reflect the date they move into routine
1.100	24-Aug-18	P Clark; D Thomson; D Dwyer	commissioning
1.101	31-Aug-18	P Clark; D Thomson; D Dwyer	2 drugs/indications with updated treatment criteria; 1 drug/indication updated to reflect the date it moves into routine commissioning

#### Changes to recent versions

General or criteria	Summary of changes					
changed	Summary of changes					
Changes to version 1.10						
Ibrutinib - routine	Ibrutinib for the treatment relapsed/ refractory chronic lymphocytic leukaemia split into two forms in light of recent update to eligibility criteria					
Ibrutinib - routine	Treatment criteria (5, 6 & 7) updated for ibrutinib for the treatment of chronic lymphocytic leukaemia with 17p deletion or TP53 mutation					
LUT1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 27-Nov-18					
Changes to version 1.10	Changes to version 1.100					
CABO3_v1.0	Recommended for routine commissioning, receiving CDF interim funding					
Cabozantinib - routine	Treatment criteria (9) added					
DIN1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 20-Nov-18					
DIN2_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 20-Nov-18					
BRE5_v1.3	Treatment criteria (4) updated					
BRE6_v1.2	Treatment criteria (4) updated					
Changes to version 1.99						
ATE2_v1.0	Moved into routine commissioning - section B of list					
BEN6_v2.1	Moved back to the CDF list (section A) to reflect that this is still commissioned via the CDF					
Changes to version 1.98						
INO1_v1.0	Recommended for routine commissioning, receiving CDF interim funding					
INO2_v1.0	Recommended for routine commissioning, receiving CDF interim funding					
Blinatumomab - routine	Treatment criteria (3 & 9) updated					
Blinatumomab - routine	Treatment criteria (3 & 9) updated					
ALE1_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18					
LNV2_v1.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18					
SOR2_v3.0	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 06-Nov-18					
Changes to version 1.97						
BEV2_v1.4	Treatment criteria around treatment breaks (10) updated					
Bendamustine - routine	Duplicate entry deleted					
Changes to version 1.96						
_	Recommended for the CDF					
PEMB6_v1.0	Recommended for the CDF					
Changes to version 1.95						
	Expected Entry into Baseline Commissioning column updated in light of final guidance being published - 16-Oct-18					
	Recommended for routine commissioning, receiving CDF interim funding					
	Treatment criteria (4) updated					
Changes to version 1.94						
ATE3_v1.0	Moved into routine commissioning - section B of list					
PEMB4_v1.0	Treatment criteria updated reflecting the change to the European Medicines Agency's (EMA) marketing authorisation; 1 drug/indication with updated treatment criteria					
Changes to version 1.93						
DIN1_v1.0	Recommended for routine commissioning, receiving CDF interim funding					
	Recommended for routine commissioning, receiving CDF interim funding					
	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018					
BEN6_v2.1	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018					
BEN2_v2.0	Moved to routine commissioning following a positive recommendation from CPAG on 8 July 2018					
ATE1_v1.1	Treatment criteria updated reflecting the change to the European Medicines Agency's (EMA) marketing authorisation					
Changes to version 1.92						
AVE2_v1.0 Moved into routine commissioning - section B of list						
Changes to version 1.91						
	Note around treatment breaks updated					
	Note around treatment breaks updated					
	Duplicate entry deleted					
Changes to version 1.90						
	Recommended for routine commissioning, receiving CDF interim funding					
	Treatment criteria (11) updated					
22						